

CURRICULUM VITAE

Timothy Fenske MD

Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:

09/1986 - 05/1990 B.S., Marquette University, Milwaukee, WI
06/1992 - 06/1994 M.D., University of Wisconsin-Madison Medical School, Madison, WI
07/1994 - 07/1997 M.S., UW-Madison, Madison, WI
07/1997 - 05/1999 M.D., University of Wisconsin-Madison Medical School, Madison, WI
(combined MD/MS degree program)

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

06/1999 - 06/2002 Resident, Internal Medicine, University of Wisconsin-Madison, Madison, WI
07/2002 - 06/2005 Fellow, Hematology/Oncology, Washington University School of Medicine / Barnes-Jewish Hospital, St. Louis, MO
07/2003 - 06/2005 Trainee, Washington Univ. Hematology Training Grant, (NIH Funded)
07/2004 ASCO/AACR Clinical Trials Workshop, Vail, CO
09/2005 - 05/2007 K30 Clinical Research Scholars Program (CRSP), Medical College of Wisconsin, Milwaukee, WI
Barnes-Jewish Hospital, St. Louis, MO

FACULTY APPOINTMENTS:

07/2005 - 07/2011 Assistant Professor, Department of Medicine,, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
07/2011 - 2017 Associate Profesor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
08/2016 - 2017 Head, Section of Hematologic Malignancies & BMT, Division of Hematology and, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:

03/2004 - 09/2005 Barnes Jewish Hospital, St. Louis, MO
07/2005 - Present Froedtert Memorial Lutheran Hospital, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
American Board of Internal Medicine	08/2002	08/2012
ABIM – Medical Oncology	11/2005	11/2015

<u>Certificates</u>	<u>Issued By</u>	<u>Issue Date</u>	<u>Expiration</u>
CPR	AHA	09/1998	07/2005

Symposium
 10/2011 - 03/2012 Co-program director and speaker, 1st Annual Controversies of Hematologic Malignancies Symposium (Milwaukee, WI)
 10/2011 - Present MCW Institutional PI, Eastern Cooperative Oncology Group
 2011 - 2012 Member, Data Review Committee, Bone Marrow Transplantation Clinical Trials Network Protocol 0401.
 04/2012 - Present Symposium Committee Co-Chair and Moderator, 9th International Chicago
 2012 - 2013 Symposium Committee Co-Chair and Moderator, 9th International
 04/2013 - Present Symposium Committee Co-Chair and Moderator, 10th International Chicago Lymphoma Symposium
 2013 - 2014 Member, Lymphoma Committee, 2014 State of the Science Symposium, Blood and Marrow Transplant Clinical Trials Network
 02/2014 - Present Abstract Reviewer and Session Chair, "Allogeneic Transplants & Autologous Transplants, " 2014 BMT Tandem Meetings
 2014 - 2015 2016 Symposium Committee Co-Chair and Organizer, Ultmann International Chicago Lymphoma Symposium
 03/2015 - 03/2020 Lymphoma Working Committee Co-Chair, Center for International Blood
 04/2016 - Present Lymphoma Steering Committee, National Cancer Institute
 2016 Abstract Reviewer and Session Chair, American Society of Hematology Annual Meeting, "Clinical Results – Autologous Transplantation"

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	Genetic susceptibility to therapy-related acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after high-dose therapy and autologous stem cell transplantation for lymphoma.
Source:	CIBMTR
Role:	Principal Investigator
PI:	Self
Dates:	02/2006 - Present
Title:	A study of cellular adoptive immunotherapy as treatment for EVB-LPD: use of autologous Epstein-Barr Virus specific cytotoxic T-lymphocytes.
Role:	Principal Investigator
PI:	Self
Dates:	2006 - Present
Title:	Outcome of patients with mantle cell lymphoma treated with autologous versus allogeneic transplantation
Source:	CIBMTR
Role:	Study Chair
Dates:	02/2008 - Present
Title:	A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
Source:	Washington University, St. Louis / Celgene
Role:	Principal Investigator
PI:	Self

Dates:	06/25/2008 - Present
Direct Funds:	\$3,000 (6 patients enrolled to date. Accrual continues)
Title:	C18083/2039/NL/US-CA: An open-label study of bendamustine hydrochloride in combination with rituximab in the treatment of patients with relapsed/refractory mantle cell lymphoma
Source:	Cephalon
Role:	Principal Investigator
PI:	Self
Dates:	04/14/2010 - Present
Direct Funds:	\$12,065 (0 patients enrolled at our site. Accrual still open)
Title:	CRAD001NUS65: An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma
Source:	Novartis
Role:	Principal Investigator
PI:	Self
Dates:	08/20/2010 - Present
Direct Funds:	\$15,250 (0 patients enrolled at our site. Accrual still open.)
Title:	A phase II study of bortezomib and temsirolimus for relapsed or refractory B-cell non-Hodgkin lymphoma.
Source:	Millennium Pharmaceuticals
Role:	Study Chair & Author
Dates:	09/01/2010 - 08/31/2013
Direct Funds:	\$485,000 (Awaiting final approval at UW-Madison and subsequent IRBs)
Title:	Clinical outcomes of hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma transformed from chronic lymphocytic leukemia, follicular lymphoma or Waldenstrom macroglobulinemia.
Source:	CIBMTR
Role:	Study co-Chair
Dates:	2010 - Present
Direct Funds:	\$0 (In protocol development phase)
<u>Non-Peer Review</u>	
Title:	A phase II study of bortezomib in combination with bendamustine and rituximab in subjects with relapsed or refractory follicular lymphoma
Source:	Millennium Pharmaceuticals
Role:	Principal Investigator
PI:	Self

Dates: 10/20/2008 - Present
Direct Funds: \$1,228 (1 patient enrolled. Study rapidly accrued nationwide)

Pending

Peer Review

Title: Rituximab/hyper-CVAD alternating with rituximab/methotrexate/cytarabine versus rituximab/bendamustine followed by autologous stem cell transplantation as first line therapy for mantle cell lymphoma patients age 65 and under.
Source: ECOG / SWOG / CALGB
Role: Study Chair (for ECOG)
Dates: 10/2009 - Present
Direct Funds: \$0 (In Protocol development phase)

Title: CLBH589E2301: A Phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin's lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant
Source: Novartis
Role: Principal Investigator
PI: Self
Direct Funds: \$27,310 (0 patients enrolled at our site. Accrual still opened.)

Prior

Peer Review

Title: A retrospective review of the results of a University of Wisconsin Bone Marrow transplantation protocol for non-Hodgkin lymphoma
Source: Departmental
Role: First Author
Dates: 2000 - 2001
Direct Funds: \$0 (Mentors were Drs. Brad Kahl and Walter Longo. Results published in 2005)

Title: A Phase II trial of the anti-CD30 monoclonal antibody SGN-30 following autologous stem cell transplantation for relapsed or refractory Hodgkin's Disease
Source: Departmental
Role: Writer & Submitter
Dates: 2002 - 2003
Direct Funds: \$0 (Mentors were Drs. Nancy Bartlett and John DiPersio. Wrote and submitted an NCI R21 grant for funding for this

study.)

Title: Phase I study to evaluate the combination of bortezomib and idarubicin in patients with relapsed or refractory acute myeloid leukemia (AML).
Source: Departmental
Role: Writer
Dates: 2004 - 2005
Direct Funds: \$0 (Research experience, mentor was Dr. Steve Devine)

Title: Effects of pre-transplant rituximab on the outcomes of autologous hematopoietic stem cell transplantation in patients with non-Hodgkin's lymphoma.
Source: CIBMTR
Role: Study Chair
Dates: 2006 - 2009
Direct Funds: \$0 (Oral presentation at American Society of Hematology Meeting (2007), with full manuscript published in 2009.)

Title: Development of ^{99m}Tc scanning as a quantitative in vivo assay to predict chemotherapy drug resistance and clinical outcome in lymphoma patients.
Source: Medical College of Wisconsin, Clinical Cancer Center
Role: Principal Investigator
PI: Self
Dates: 10/2007 - 06/2011
Direct Funds: \$40,000 (Accrual goal (21 pts) met in May 2010.)

Title: Characterization of a novel transgenic mouse model of t(8;21) AML in which expression of the AML1/ETO fusion protein is targeted to the stem cell compartment. A separate project involved the genetics of susceptibility to alkylator-induced malignancies in inbred mice.
Source: Departmental
Role: Post-doctoral fellow
Direct Funds: \$0

Non-Peer Review

Title: Organization of B. subtilis chromatin
Source: Departmental
Role: Undergraduate student
Dates: 1989 - 1990
Direct Funds: \$0 (Undergraduate Senior Research Project, Marquette University)

Title: Investigated HLA class II gene polymorphism and linkage between different HLA loci. Developed new assays for PCR amplification of small tandem repeat loci to quantitate donor chimerism in patients following allogeneic stem cell transplantation.

Source: Departmental
 Role: R&D Technologist – Blood Center of Southeastern Wisconsin
 Dates: 1989 - 1992
 Direct Funds: \$0

Title: Project characterizing cytokine (IL-2 and IL-15) receptor Subunits and signal transduction pathways in myeloid and monocytic cells.

Source: Departmental
 Role: Graduate student in Dr. Paul Sondel's lab
 Dates: 1994 - 1996
 Direct Funds: \$0

Title: Project focusing on developing a transgenic mouse model to study the role of E2F transcription factors in hepatocyte proliferation.

Source: Departmental
 Role: Graduate student in Dr. Peggy Farnham's lab
 Dates: 1996 - 1997
 Direct Funds: \$0

Title: Multiple ECOG lymphoma trials-ECOG 4402 (follicular lymphoma), ECOG 3402 (limited stage large cell lymphoma), ECOG 3404 (advanced stage large cell lymphoma), and ECOG 1405 (mantle cell lymphoma)

Source: ECOG
 Role: Institutional enrolling Investigator
 Dates: 2005 - 2009
 Direct Funds: \$1,775 (Enrolled 1-4 patients on each of these trials.)

Title: A randomized, open-label, multicenter study of VELCADE with rituximab or rituximab alone in subjects with relapsed or refractory, rituximab naïve or sensitive follicular B-cell non-Hodgkin's lymphoma

Source: Johnson & Johnson/Millennium Pharmaceuticals
 Role: Institutional Principal Investigator
 PI: Self
 Dates: 09/25/2006 - 04/20/2009
 Direct Funds: \$22,475 (3 patients enrolled. We were

one of the only U.S. sites successful in enrolling on this study.)

Title: Phase III Rituxan/BEAM vs. Bexxar/BEAM with autologous hematopoietic stem cell transplantation for persistent or relapsed chemotherapy sensitive diffuse large B-cell non-Hodgkin's lymphoma.

Source: BMT CTN

Role: Institutional Principal Investigator

PI: Self

Dates: 2006 - 2009

Title: Outcome of patients with Burkitt lymphoma treated at two academic medical centers between 1996 and 2008.

Source: Departmental, collaboration with Washington University

Role: Principal Investigator

PI: Self

Dates: 2009 - 2011

Direct Funds: \$1,500 (Froedtert Foundation)

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Local

Extranodal MALT lymphoma, Medical College of Wisconsin Division of Gastroenterology Case Conference, Milwaukee, WI, 03/2006

"Chronic Myeloid Leukemia" lecture given to patients and caregivers, Leukemia and Lymphoma Society, Spring Leukemia/MDS Symposium, Madison, WI, 05/2006

"Paving the way for progress: Clinical trials in blood cancers", Leukemia and Lymphoma Society's patient education series, Waukesha, WI, 03/2007

Non-Hodgkin Lymphoma, MCW/Froedtert Community Health Lecture Series, Milwaukee, WI, 09/2007

Lymphoma Transplant, Hematology Update, Medical College of Wisconsin, Milwaukee, WI, 01/2008

"Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research", Kenosha, WI, 03/2008

Lymphoma Transplant and Hodgkin Lymphoma, Hematology Update, Medical College of Wisconsin, Milwaukee, WI, 01/2009

"Aggressive B-cell NHL", Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, 05/2009

Update in Hodgkin Lymphoma, Lake Country Hematology Symposium, Delafield, WI, 08/2009

Lymphoma Overview, lecture given to Physician Assistant students, Marquette University, Milwaukee, WI, 11/2009

"CPC" discussant, Medical College of Wisconsin Conference, Milwaukee, WI, 12/07/2009

Aggressive NHL and HL, Hematology Update, Medical College of Wisconsin, Milwaukee, WI, 03/31/2010

"Aggressive B-cell NHL", Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, 03/2010

"Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research", Kenosha, WI, 05/2010

Lymphoma Overview, lecture given to Physician Assistant students, Marquette University, Milwaukee, WI, 11/2010

"Extranodal MALT lymphoma" case presentation given for Medical College of Wisconsin Division of Gastroenterology Case Conference. Milwaukee

"Non-Hodgkin Lymphoma" MCW/Froedtert Community Health Lecture Series, Milwaukee

"Lymphoma Transplant", Hematology Update, Medical College of Wisconsin, Milwaukee

"Lymphoma Transplant and Hodgkin Lymphoma", Hematology Update, Medical College of Wisconsin,

Milwaukee

"Lymphoma Overview" lecture given to Physician Assistant students, Marquette University, Milwaukee

"CPC" discussant, Medical College of Wisconsin Conference, Milwaukee

"Aggressive NHL and HL", Hematology Update, Medical College of Wisconsin, Milwaukee, WI

"Selected hematopathology cases in leukemia and lymphoma", Controversies of Hematologic Malignancies Symposium, Milwaukee

"Lymphoma Overview" and "Monitoring for Relapse," 2nd Annual Lymphoma Survivors Meeting, Leukemia & Lymphoma Society, Milwaukee

"Minimal Residual Disease analysis for lymphoma"

"Extranodal MALT lymphoma" case presentation given for Medical College of Wisconsin Division of Gastroenterology Case Conference. Milwaukee

"Non-Hodgkin Lymphoma" MCW/Froedtert Community Health Lecture Series, Milwaukee

"Lymphoma Transplant", Hematology Update, Medical College of Wisconsin, Milwaukee

"Lymphoma Transplant and Hodgkin Lymphoma", Hematology Update, Medical College of Wisconsin, Milwaukee

"Lymphoma Overview" lecture given to Physician Assistant students, Marquette University, Milwaukee

"CPC" discussant, Medical College of Wisconsin Conference, Milwaukee

"Aggressive NHL and HL", Hematology Update, Medical College of Wisconsin, Milwaukee, WI

"Selected hematopathology cases in leukemia and lymphoma", Controversies of Hematologic Malignancies Symposium, Milwaukee

"Lymphoma Overview" and "Monitoring for Relapse," 2nd Annual Lymphoma Survivors Meeting, Leukemia & Lymphoma Society, Milwaukee

"Minimal Residual Disease analysis for lymphoma"

Regional

Standard Therapy for Younger Patients with Mantle Cell Lymphoma Should Include Stem Cell Transplantation, International Chicago Lymphoma Symposium, Chicago, IL, 04/2011

10/2014 - Present

10/2014 - Present

"Chronic Myeloid Leukemia" lecture given to patients and caregivers, Leukemia and Lymphoma Society, Spring Leukemia/MDS Symposium, Madison

"Paving the way for progress: Clinical trials in blood cancers" Leukemia and Lymphoma Society's patient education series, Waukesha

"Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research", Kenosha

"Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research", Kenosha

"Aggressive B-cell NHL" lecture given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison

"Aggressive B-cell NHL" lecture given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison

"Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma (Clinical Care Options Oncology)"

- 3/15/11: Fox Valley Hematology/Oncology (Appleton, WI)

- 6/1/11: Bellin Health (Green Bay, WI)

- 7/12/11: Wheaton Franciscan Healthcare (Racine, WI)

- 8/8/11: Bay Regional Medical Center (Bay City, MI)

"Frontline therapy for follicular lymphoma: so many options, so little consensus", Controversies of Hematologic Malignancies Symposium

"Relapsed and Refractory Diffuse Large B-Cell Lymphoma: Are We Making Any Progress?" Keynote Lecture for Wisconsin Oncology Network Meeting, Madison

"Radiographic imaging in lymphoma: benefits and risks" Leukemia and Lymphoma Society Patient and Caregiver Meeting on Lymphoma, Madison

"Aggressive B-cell non-Hodgkin lymphomas" and "Mantle cell lymphoma." Lymphoma Research Foundation Patient and Caregiver Meeting

"What's New in Lymphoma?" Third annual Advances in Hematology and Oncology Symposium, Green Bay

"Mantle cell lymphoma" unbranded disease-focused presentations given at various sites across the Midwest (2014-2016).

"New Developments in Transplant for Lymphoma: A practicing clinician's view for 2016", Controversies of Hematologic Malignancies Symposium

"Transplant in Non-Hodgkin's Lymphoma" unbranded disease-focused presentation, Glenview

"Chronic Myeloid Leukemia" lecture given to patients and caregivers, Leukemia and Lymphoma Society, Spring Leukemia/MDS Symposium, Madison

"Paving the way for progress: Clinical trials in blood cancers" Leukemia and Lymphoma Society's patient education series, Waukesha

"Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research", Kenosha

"Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research", Kenosha

"Aggressive B-cell NHL" lecture given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison

"Aggressive B-cell NHL" lecture given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison

"Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma (Clinical Care Options Oncology)"

- 3/15/11: Fox Valley Hematology/Oncology (Appleton, WI)
- 6/1/11: Bellin Health (Green Bay, WI)
- 7/12/11: Wheaton Franciscan Healthcare (Racine, WI)
- 8/8/11: Bay Regional Medical Center (Bay City, MI)

"Frontline therapy for follicular lymphoma: so many options, so little consensus", Controversies of Hematologic Malignancies Symposium

"Relapsed and Refractory Diffuse Large B-Cell Lymphoma: Are We Making Any Progress?" Keynote Lecture for Wisconsin Oncology Network Meeting, Madison

"Radiographic imaging in lymphoma: benefits and risks" Leukemia and Lymphoma Society Patient and Caregiver Meeting on Lymphoma, Madison

"Aggressive B-cell non-Hodgkin lymphomas" and "Mantle cell lymphoma." Lymphoma Research Foundation Patient and Caregiver Meeting

"What's New in Lymphoma?" Third annual Advances in Hematology and Oncology Symposium, Green Bay

"Mantle cell lymphoma" unbranded disease-focused presentations given at various sites across the Midwest (2014-2016).

"New Developments in Transplant for Lymphoma: A practicing clinician's view for 2016", Controversies of Hematologic Malignancies Symposium

"Transplant in Non-Hodgkin's Lymphoma" unbranded disease-focused presentation, Glenview

National

Optimizing therapy for CD20-expressing B-cell malignancies: A focus on diffuse large B-cell lymphoma, RHD Medical Center Grand Rounds, Dallas, TX, 06/2007

"Novel Approaches for Relapsed/Refractory Follicular Lymphoma" as part of the CME series "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL (Clinical Care Options Oncology)", Lawrence & Memorial Medical Center, New London, CT, 04/13/2010

"Novel Approaches for Relapsed/Refractory Follicular Lymphoma" as part of the CME series "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL (Clinical Care Options Oncology)", Halifax Medical Center, Daytona Beach, FL, 04/28/2010

"Novel Approaches for the Treatment of Diffuse Large B-cell lymphoma" and "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL (Clinical Care Options Oncology)", Union Memorial Hospital, Baltimore, MD, 05/14/2010

"Multidisciplinary Approaches for the Diagnosis and Optimal anagement of Mantle Cell Lymphoma," and "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL., Covenant Women and Children's Hospital, Lubbock, TX, 08/16/2010

"Multidisciplinary Approaches for the Diagnosis and Optimal anagement of Mantle Cell Lymphoma," as part of the CME series "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL, Phelps County Regional Medical Center, Rolla, MO, 08/30/2010

"Novel Approaches for the Treatment of Diffuse Large B-cell lymphoma" and "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL (Clinical Care Options Oncology), Thompson Cancer Survival Center, Knoxville, TN, 09/13/2010

"Novel Approaches for the Treatment of Diffuse Large B-cell lymphoma" and "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL (Clinical Care Options Oncology), Claxton-Hepburn Medical Center, Ogdensburg, NY, 09/17/2010

"Optimizing therapy for CD20-expressing B-cell malignancies: A focus on diffuse large B-cell lymphoma" RHD Dallas

"Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL" (Clinical Care Options Oncology)

- 4/13/10: Lawrence & Memorial Medical Center (New London, CT)

- 4/28/10: Halifax Medical Center (Daytona Beach, FL)

- 5/14/10: Union Memorial Hospital (Baltimore, MD)

- 8/16/10: Covenant Women and Children's Hospital (Lubbock, TX)

- 8/30/10: Phelps County Regional Medical Center (Rolla, MO)

- 9/13/10: Thompson Cancer Survival Center (Knoxville, TN)

"Workshop With the Experts: Overcoming Barriers to Optimal Treatment of Non- Hodgkin Lymphoma" (Clinical Care Options Oncology)

- 06/01/11: Bellin Health (Green Bay, WI)

- 07/09/11: Lawrence Memorial Hospital (Lawrence, KS)

Member, Lymphoma Committee, Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma at national sales training meeting (October 2014)

Invited lecture "Diffuse Large B-cell lymphoma: How do we move forward?"

"Optimizing therapy for CD20-expressing B-cell malignancies: A focus on diffuse large B-cell lymphoma" RHD Dallas

"Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL" (Clinical Care Options Oncology)

- 4/13/10: Lawrence & Memorial Medical Center (New London, CT)

- 4/28/10: Halifax Medical Center (Daytona Beach, FL)

- 5/14/10: Union Memorial Hospital (Baltimore, MD)

- 8/16/10: Covenant Women and Children's Hospital (Lubbock, TX)

- 8/30/10: Phelps County Regional Medical Center (Rolla, MO)

- 9/13/10: Thompson Cancer Survival Center (Knoxville, TN)

"Workshop With the Experts: Overcoming Barriers to Optimal Treatment of Non- Hodgkin Lymphoma" (Clinical Care Options Oncology)

- 06/01/11: Bellin Health (Green Bay, WI)

- 07/09/11: Lawrence Memorial Hospital (Lawrence, KS)

Member, Lymphoma Committee, Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma at national sales training meeting (October 2014)

Invited lecture "Diffuse Large B-cell lymphoma: How do we move forward?"

Hematology/Oncology Grand Rounds

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma at national sales training meeting (November 2016)

"Transplant in Non-Hodgkin Lymphoma" - unbranded lecture

- Jan 2016: Consultant to develop slide set

- Sept 2016: San Francisco, CA

- Feb 2017: Washington University in St Louis, MO

- March 2017: Evanston, IL

- 6/1/17: Santa Rosa, CA

- 10/28/16: Montefiore Medical Center (New York City, New York)

- 11/4/16: Washington Cancer Institute (Washington, DC)

- 4/24/17: NH Forsyth Medical Center (Winston-Salem, NC)

Invited lecturer on "What is the best first-line therapy for younger patients with mantle cell lymphoma?" Great Debates & Updates in Hematologic Malignancies, New York City, NY (April 8, 2017)

Invited lecturer on "Next Generation Sequencing-based Minimal Residual Disease Analysis in B- cell lymphomas." Eastern Cooperative Oncology group meeting; Hematologic Malignancies session, Washington, D.C. (May 5, 2017).

Hematology/Oncology Grand Rounds

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma at national sales training meeting (November 2016)

"Transplant in Non-Hodgkin Lymphoma" - unbranded lecture

- Jan 2016: Consultant to develop slide set

- Sept 2016: San Francisco, CA

- Feb 2017: Washington University in St Louis, MO

- March 2017: Evanston, IL

- 6/1/17: Santa Rosa, CA

- 10/28/16: Montefiore Medical Center (New York City, New York)

- 11/4/16: Washington Cancer Institute (Washington, DC)

- 4/24/17: NH Forsyth Medical Center (Winston-Salem, NC)

Invited lecturer on "What is the best first-line therapy for younger patients with mantle cell lymphoma?"

Great Debates & Updates in Hematologic Malignancies, New York City, NY (April 8, 2017)

Invited lecturer on "Next Generation Sequencing-based Minimal Residual Disease Analysis in B- cell

lymphomas." Eastern Cooperative Oncology group meeting; Hematologic

Malignancies session, Washington, D.C. (May 5, 2017).

International

Featured in a full page advertisement, Invited to prepare 6 CME oncology case presentations, Community Oncology, 09/2009 - 04/2010

Invited lecture on "Autologous stem cell transplant should be a treatment option for relapsed mantle cell lymphoma." 12th International Ultmann Chicago Lymphoma Symposium, Chicago, IL (April 25, 2015).

Invited lecturer on "Transplant and Non-Hodgkin Lymphoma" for Product Theater presentation at the 2016 BMT Tandem meeting, Honolulu, HI (Feb 20, 2016)

Moderator, "No role for surveillance imaging in lymphoma." 13th International Ultmann Chicago Lymphoma Symposium, Chicago, IL (May 6, 2016).

Presenter, "Meet the Professor" session on "Unusual Lymphomas and the Role of Autografting and Allografting." 2017 ASBMT Annual Meeting, Orlando, Florida (Feb 23, 2017).

Moderator, "Standard Therapy for Younger Patients with Mantle Cell Lymphoma Should Include Stem Cell Transplantation." International Chicago Lymphoma Symposium, Chicago, IL (April 2011)

Invited lecturer on "Conventional Therapy and Novel Agents for Follicular Lymphoma" at an educational session at the Bone Marrow Transplantation Tandem Meeting (San Diego, CA, Feb 2012).

Moderator, "High Risk Patients with DLBCL Should Undergo a Stem Cell Transplant as Part of Front-line Treatment." International Chicago Lymphoma Symposium, Chicago

Invited lecturer on "Timing of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma." 10th International Chicago Lymphoma Symposium, Chicago, IL (April 27, 2013)

Moderator, "Patients with mantle cell lymphoma should receive an autotransplant in first remission." 11th International Ultmann Chicago Lymphoma Symposium, Chicago, IL (May 3, 2014)

Moderator, "Standard Therapy for Younger Patients with Mantle Cell Lymphoma Should Include Stem Cell Transplantation." International Chicago Lymphoma Symposium, Chicago, IL (April 2011)

Invited lecturer on "Conventional Therapy and Novel Agents for Follicular Lymphoma" at an educational session at the Bone Marrow Transplantation Tandem Meeting (San Diego, CA, Feb 2012).

Moderator, "High Risk Patients with DLBCL Should Undergo a Stem Cell Transplant as Part of Front-line Treatment." International Chicago Lymphoma Symposium, Chicago

Invited lecturer on "Timing of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma." 10th International Chicago Lymphoma Symposium, Chicago, IL (April 27, 2013)

Moderator, "Patients with mantle cell lymphoma should receive an autotransplant in first remission." 11th International Ultmann Chicago Lymphoma Symposium, Chicago, IL (May 3, 2014)

Invited lecture on "Autologous stem cell transplant should be a treatment option for relapsed mantle cell

lymphoma." 12th International Ultmann Chicago Lymphoma Symposium, Chicago, IL (April 25, 2015).

Invited lecturer on "Transplant and Non-Hodgkin Lymphoma" for Product Theater presentation at the 2016 BMT Tandem meeting, Honolulu, HI (Feb 20, 2016)

Moderator, "No role for surveillance imaging in lymphoma." 13th International Ultmann Chicago Lymphoma Symposium, Chicago, IL (May 6, 2016).

Presenter, "Meet the Professor" session on "Unusual Lymphomas and the Role of Autografting and Allografting." 2017 ASBMT Annual Meeting, Orlando, Florida (Feb 23, 2017).

PEER REVIEWED WORKSHOPS/PRESENTATIONS:

Local

Bilateral leg pain and weakness in a patient with polycythemia vera, American College of Physicians / American Society of Internal Medicine, Wisconsin Chapter Annual Meeting, Milwaukee, WI, 09/2001

See "Abstracts"

See "Abstracts"

Regional

Targeting AML1-ETO to the hematopoietic stem cell compartment induces myeloproliferative disease in mice, ASH Annual Meeting, San Diego, CA, 2003

National

Interleukin-2 mediated activation of JAK3 in the absence of a detectable 64 kDa common gamma chain, FASEB/ASBMT Annual Meeting, New Orleans, LA, 1996

Genetic basis of susceptibility to alkylator chemotherapy-related leukemia, ASH Annual Meeting, San Diego, CA, 2003

A mouse model of alkylator-induced myelodysplastic syndrome, American Society of Hematology Annual Meeting, Atlanta, GA, 2005

Susceptibility to alkylator-induced cancer is a heritable trait, American Society of Hematology Annual Meeting, Atlanta, GA, 2005

Pre-transplant rituximab therapy is associated with improved progression-free and overall survival in patients undergoing autologous stem cell transplantation for diffuse large B-cell, American Society of Hematology Annual Meeting, Atlanta, GA, 2007

Outpatient Hypomethylating therapy for acute myelogenous leukemia (AML) can induce sustained responses with low induction mortality, American Society of Hematology Annual Meeting, New Orleans, LA, 2009

Methotrexate-induced CNS Hodgkin-like lymphoproliferative disorder: a case report, Joint Meeting of the Society for NeuroOncology and the American Association of Neurological Surgeons /Congress of Neurological Surgeons, New Orleans, LA, 2009

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma, American Society of Hematology Annual Meeting, New Orleans, LA, 2009

COMMITTEE SERVICE:

Medical College of Wisconsin

2007 Member, Heme/Onc Fellowship Admission Committee, Department of Medicine, Medical College of Wisconsin

10/2008 - 04/2010 Member, Institutional Review Board (IRB), Froedtert & Medical College of Wisconsin

2008 Member, Heme/Onc Fellowship Admission Committee, Department of Medicine, Medical College of Wisconsin

2009 Member, Heme/Onc Fellowship Admission Committee, Department of Medicine, Medical College of Wisconsin

MEDICAL COLLEGE TEACHING ACTIVITIES:

Medical Student Education

2001 - Present Instructor in second-year medical student Hematology course, University

2004 - 2005 Instructor in second-year medical student Hematology course, Washington University School of Medicine

2006 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2006 - 2007 2009 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2007 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2009 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2010 Instructor in the "General Principles" Module of the M1 Curriculum, "Neoplasia and Carcinogenesis"

2010 - 2011 Instructor in the "General Principles" Module of the M1 Curriculum,

2011 - Present to 2016 Instructor in the "Hematology & Neoplasia" Module of the M2 Integrated Curriculum
of Wisconsin Medical School.
"Neoplasia and Carcinogenesis"

Resident and Fellow Education

2005 - 2007 "Lymphoma for the Internist" lecture given at MCW Resident Noon Conference Series

2005 - 2010 Instruction of fourth-year medical students, interns, residents, and fellows rotating through the inpatient Heme/Onc service, Oncology consultation service, and outpatient Heme/Onc clinic

2005 - Present to 2017 "Lymphoma for the Internist" lecture given at MCW (1-2 times per year)

2005 - Present to 2017 Instruction of fourth-year medical students, interns, residents, and

2006 - 2010 "Hodgkin Lymphoma" lecture given to the Heme/Onc fellows as part of the core curriculum series.

2006 - Present to 2013 "Hodgkin Lymphoma" lecture given to the Heme/Onc fellows as part of

2008 - 2010 "Low-grade Non-Hodgkin Lymphoma" lecture given to the Heme/Onc fellows as part of the core curriculum series

2008 - Present to 2014 "Low-grade Non-Hodgkin Lymphoma" lecture given to the Heme/Onc

2008 - Present to 2013 "Aggressive Non-Hodgkin Lymphoma" lecture given to the Heme/Onc

2009 - 2011 "Clinicopathologic Case Conference" lectures given to Medicine

2009 "Lymphoma for the Internist" lecture given at MCW Resident Noon Conference Series

2014 - 2016 "Autologous hematopoietic cell transplantation" lecture given to the Residents
Heme/Onc fellows as part of the core curriculum series.
Resident Noon Conference Series
the core curriculum series.
fellows rotating through the inpatient Heme/Onc service, Oncology consultation service, and outpatient Heme/Onc clinic.
fellows as part of the core curriculum series.

Continuing Medical Education

01/2008 "Lymphoma Transplant", Hematology Update

01/2009 "Lymphoma Transplant and Hodgkin Lymphoma", Hematology Update

09/2009 - 04/2010 Presented six educational oncology cases on QuantiaMD (A CME web site)

03/31/2010 "Aggressive NHL and HL", Hematology Update
Milwaukee, WI

EXTRAMURAL TEACHING:

Community/Lay Public

05/2006 - Present "Chronic Myeloid Leukemia" lecture given to patients and caregivers, Leukemia and Lymphoma Society, Spring Leukemia/MDS Symposium, Madison, WI

05/2006 Leukemia and Lymphoma Society, Spring Leukemia/MDS Symposium, Madison, WI, "Chronic Myeloid Leukemia" lecture given to patients and caregivers

03/2007 Leukemia and Lymphoma Society's patient education series, Waukesha, WI, "Paving the way for

progress: Clinical trials in blood cancers”

09/2007 - Present "Non-Hodgkin Lymphoma" lecture given as part of Froedtert/ MCW
 09/2007 Froedtert/MCW Community Health series, “Non-Hodgkin Lymphoma” lecture
 03/2008 UW - Parkside, Kenosha, WI, “Biology of Cancer” course. Lectured on “Clinical oncology and clinical oncology research”

05/2009 Leukemia and Lymphoma Society’s spring Leukemia/Lymphoma symposium, Madison, WI, “Aggressive B-cell NHL”, lecture given to patients and caregivers

05/2009 - Present "Aggressive B-cell NHL", lecture given to patients and caregivers, as
 11/2009 Marquette University, “Lymphoma Overview” lecture given to Physician Assistant students

03/2010 Leukemia and Lymphoma Society’s spring Leukemia/Lymphoma symposium, Madison, WI, “Aggressive B-cell NHL”, lecture given to patients and caregivers

04/2010 - Present "Hodgkin lymphoma" and "Non-Hodgkin lymphoma" lectures
 11/2010 Marquette University, “Lymphoma Overview” lecture given to Physician Assistant students

2010 - 2013 "Aggressive B-cell NHL", lecture given to patients and caregivers, as
 04/2014 - Present Director, "Lymphoma Survivorship Conference", Leukemia &
 10/2014 - Present "Aggressive NHL", Lymphoma Research Foundation Patient Forum

05/2015 - Present "Clinical Trials in Lymphoma" lecture given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium (Madison, WI)

09/2016 - Present "Aggressive Non-Hodgkin lymphomas and Hodgkin lymphoma" lecture
 10/2016 - Present "Diffuse Large B-Cell Lymphoma and other Aggressive B-cell lymphomas" lecture given to patients and caregivers as part of the Lymphoma Research Foundation's North American Educational Forum on Lymphoma (Chicago, IL).
 Society's spring Leukemia/Lymphoma symposium (Milwaukee, WI)
 Community Health series.
 Leukemia/Lymphoma symposium, Madison, WI
 Lymphoma Society, Wisconsin Chapter (Milwaukee, WI).
 given to patients and caregivers, as part of the Leukemia and Lymphoma and Lymphoma Society's patient education series, Waukesha, WI
 given to MCW Division of Hematology and Oncology Clinical Research Coordinators
 given to patients and caregivers, as part of the Leukemia and Lymphoma

Medical Student Education

2001 University of Wisconsin Medical School, Instructor in second-year medical student Hematology course

2004 - 2005 Washington University School of Medicine, Instructor in second-year medical student Hematology course

Resident and Fellow Education

03/2008 - Present and 05/2010 "Biology of Cancer" course at UW-Parkside. Lectured on "Clinical
 2009 - Present to 2015 "Lymphoma Overview" lecture given to Physician Assistant students at
 06/2014 - Present "Autologous Hematopoietic Cell Transplantation, " lecture given to
 01/2015 - Present "Lymphoma" lecture given to Froedtert Hospital inpatient and outpatient
 Nursing Staff
 Froedtert Hospital inpatient Heme/Onc RNs.
 Heme/Onc RNs.
 Undergraduate
 oncology and clinical oncology research", Kenosha, WI
 Marquette University.

Continuing Medical Education

06/2007 - Present Optimizing therapy for CD20-expressing B-cell malignancies: A focus
 06/2007 RHD Medical Center Grand Rounds, Dallas, TX, Optimizing therapy for CD20-expressing B-cell malignancies: A focus on diffuse large B-cell lymphoma”
 01/2008 - Present "Lymphoma Transplant", Hematology Update, Medical College of
 01/2009 - Present "Lymphoma Transplant and Hodgkin Lymphoma", Hematology Update,
 08/2009 Delafield, WI, “Update in Hodgkin Lymphoma” Lake Country Hematology Symposium, featured several nationally recognized speakers

09/2009 - 04/2010 Presented six educational oncology cases on QuantiaMD (A CME
 09/2009 - 04/2010 Presented six educational oncology cases on QuantiaMD (A CME
 03/31/2010 - Present "Aggressive NHL and HL", Hematology Update, Medical College of
 04/13/2010 Lawrence & Memorial Medical Center, "Novel Approaches for Relapsed/Refractory Follicular
 Lymphoma" as part of the CME series "Spanning the Continuum of Care: Optimizing Patient
 Outcomes in NHL (Clinical Care Options Oncology)
 04/28/2010 Halifax Medical Center, "Novel Approaches for Relapsed/Refractory Follicular Lymphoma"
 as part of the CME series "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL
 (Clinical Care Options Oncology)
 05/14/2010 Union Memorial Hospital, "Novel Approaches for the Treatment of Diffuse Large B-cell
 Lymphoma" as part of the CME series "Spanning the Continuum of Care: Optimizing Patient
 Outcomes in NHL (Clinical Care Options Oncology)
 08/30/2010 Phelps County Regional Medical Center, "Multidisciplinary Approaches for the Diagnosis and
 Optimal Management of Mantle Cell Lymphoma," as part of the CME series "Spanning the
 Continuum of Care: Optimizing Patient Outcomes in NHL (Clinical Care Options Oncology)
 2010 - Present "Spanning the Continuum of Care: Optimizing Patient Outcomes in
 2011 - Present "Workshop With the Experts: Overcoming Barriers to Optimal
 2016 - Present "The Healthy Days Initiative: Moving Toward Personalized Lymphoma
 Dallas, TX
 Wisconsin, Milwaukee, WI
 web site)
 NHL" (Clinical Care Options Oncology)
 - 04/13/10 Lawrence & Memorial Medical Center (New London, CT)
 - 08/16/10 Covenant Women and Children's Hospital (Lubbock, TX)
 - 08/30/10 Phelps County Regional Medical Center (Rolla, MO)
 - 07/09/11 Lawrence Memorial Hospital (Lawrence, KS)
 - 11/04/16 Washington Cancer Institute (Washington, DC)
 - 04/24/17 NH Forsyth Medical Center (Winston-Salem, NC)
 on diffuse large B-cell lymphoma" RHD Medical Center Grand Rounds
 - 04/13/10 Lawrence & Memorial Medical Center (New London, CT)
 - 04/28/10 Halifax Medical Center (Daytona Beach, FL)
 - 05/14/10 Union Memorial Hospital (Baltimore, MD)
 - 09/13/10 Thompson Cancer Survival Center (Knoxville, TN)
 - 06/01/11 Bellin Health (Green Bay, WI
 Therapy for Relapsed/Refractory Follicular Lymphoma"
 - 10/28/16 Montefiore Medical Center (New York City, New York)

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Medical Students

Stacy Parker, Medical College of Wisconsin, 2009 Mentored in writing a case series
 Sara Torgerson, Medical College of Wisconsin, 2009 - 2010 Mentored in writing a case report
 Terence Mukonje, Medical College of Wisconsin, 04/2010 - Present shadow in outpatient clinic (04/2010
 – present), and mentoring in writing a case report (2010).
 Amy Braden, Medical College of Wisconsin, 2010 - 2011 Mentoring in analyzing a retrospective case
 series
 Sirisha Paruchuri, Medical College of Wisconsin, 2010 Mentoring in writing a case report

Clinical/Research Fellows

Christopher Hake, Medical College of Wisconsin, 2007 - 2008 Mentored in writing a review article
 Leena Varkey, Medical College of Wisconsin, 2011 Mentoring in writing a review article on Aggressive B-
 cell non-Hodgkin Lymphoma for Hospital Physician Hematology Board Review Manual
 Ravi Pingali, Medical College of Wisconsin, 2011 - 2012 Mentoring in analyzing and writing up a case
 series on autologous stem cell transplantation for mantle cell lymphoma
 Robert Cornell, Medical College of Wisconsin, 2011 Mentoring in writing a review article on Low Grade
 non-Hodgkin Lymphoma for Hospital Physician Hematology Board Review Manual

Residents

Heather Benjamin, Medical College of Wisconsin, 2008 Mentored in writing a case report
Tara Kroll, Medical College of Wisconsin, 2009 - 2010 Mentored in writing a case report
Brian Aebly, Medical College of Wisconsin, 2009 - 2010 Mentoring in writing a case report
Laura Farrington, Medical College of Wisconsin, 2009 - 2010 Mentoring in analyzing and writing up a large retrospective series of Burkitt lymphoma

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. **Fenske TS**, Baxter-Lowe LA. Characterization of a novel DQB1 allele associated with HLADQw3: Implications for oligotyping. *Human Immunology* 33: 224-227, 1992.
2. **Fenske TS**, Baxter-Lowe LA. Two novel HLA-DQB1*06 alleles reveal additional heterogeneity of HLA-DQw1. *Tissue Antigens* 40: 49-52, 1992.
3. Farner NL, Gan J, de Jong JLO, Leary TP, **Fenske TS**, Buckley P, Dunlap S, Sondel PM. Alteration of the CD34+ Tf-1b cell line profile in response to long-term exposure to IL-15. *Cytokine* 9 (5): 316-27, 1997.
4. Monson NL, **Fenske TS** (published incorrectly as "**Fenske TJ**"), Wei S, Okragly AJ, de Jong JL, Haak-Frendscho M, O'Shea J, Djeu J, Sondel PM. A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line, Tf-1?2. *Journal of Leukocyte Biology* 69(3):419-25, 2001.
5. **Fenske TS**, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. *Proceedings of the National Academy of Sciences of the United States of America* 101(42): 15184-9, 2004.
6. **Fenske TS**, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, Garry McCoy A, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma. *Leukemia and Lymphoma* 46(10): 1441-8, 2005.
7. **Fenske TS**, McMahan, C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. *Cancer Research* 66(10): 5029-38, 2006.
8. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the Treatment of Patients with Very High-Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy. *Haemophilia* 13(1): 46-50, 2007.
9. **Fenske TS**, Benjamin H, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization. *Nature Clinical Practice Oncology* 5(11): 677-81, 2008.
10. Parker SM, Olteanu H, VanTuinen P, Lawton CA, Schultz CJ, Christians KK, **Fenske TS**. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. *International Journal of Hematology* 90(5): 616-622, 2009.
11. **Fenske TS**, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). *Biology of Blood and Marrow Transplantation* 15(11): 1455-64, 2009.
12. Kroll T, Ames M, **Fenske TS**. Successful management of pregnancy occurring in a chronic myeloid leukemia patient on dasatinib. *Leukemia and Lymphoma* 51(9): 1-3, 2010
13. Torgerson S, Tinguely M, **Fenske TS**. Intracranial Hodgkin lymphoma: case report and review of the literature. *Journal of Neuro-oncology* 102(2): 329-334 (2011)
14. Olteanu H, **Fenske TS**, Harrington AM, Kroft SH. CD23 expression in follicular lymphoma: clinicopathologic correlations. *American Journal of Clinical Pathology* 135(1): 46-53, 2011
15. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston NW, Carson K, Bartlett NL. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 118(19): 5119-25 (2011)

16. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN. Conditioning regimens for allotransplant for diffuse large B-cell lymphoma – myeloablative or reduced intensity? Blood Epub ahead of print, Sept 24 (2012)
17. **Fenske TS**, Baxter-Lowe LA. Characterization of a novel DQB1 allele associated with HLA-DQw3: Implications for oligotyping. *Human Immunology* 33: 224-227, 1992.
18. **Fenske TS**, Baxter-Lowe LA. Two novel HLA-DQB1*06 alleles reveal additional heterogeneity of HLA-DQw1. *Tissue Antigens* 40: 49-52, 1992.
19. Farner NL, Gan J, de Jong JLO, Leary TP, **Fenske TS**, Buckley P, Dunlap S, Sondel PM. Alteration of the CD34+ Tf-1b cell line profile in response to long-term exposure to IL-15. *Cytokine* 9 (5): 316-27, 1997.
20. Monson NL, **Fenske TS** (published incorrectly as "**Fenske TJ**"), Wei S, Okragly AJ, de Jong JL, Haak-Frendscho M, O'Shea J, Djeu J, Sondel PM. A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line, Tf-1?2. *Journal of Leukocyte Biology* 69(3):419-25, 2001.
21. **Fenske TS**, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. *Proceedings of the National Academy of Sciences of the United States of America* 101(42): 15184-9, 2004.
22. **Fenske TS**, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, Garry McCoy A, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma. *Leukemia and Lymphoma* 46(10): 1441-8, 2005.
23. **Fenske TS**, McMahan C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. *Cancer Research* 66(10): 5029-38, 2006.
24. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the Treatment of Patients with Very High-Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy. *Haemophilia* 13(1): 46-50, 2007.
25. **Fenske TS**, *Benjamin H, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. *Nature Clinical Practice Oncology* 5(11): 677-81, 2008.
26. *Parker SM, Olteanu H, VanTuinen P, Lawton CA, Schultz CJ, Christians KK, **Fenske TS**. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. *International Journal of Hematology* 90(5): 616-622, 2009.
27. **Fenske TS**, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). *Biology of Blood and Marrow Transplantation* 15(11): 1455-64, 2009.
28. *Kroll T, Ames M, **Fenske TS**. Successful management of pregnancy occurring in a chronic myeloid leukemia patient on dasatinib. *Leukemia and Lymphoma* 51(9): 1-3, 2010.
29. *Torgerson S, *Tinguely M, **Fenske TS**. Intracranial Hodgkin lymphoma: case report and review of the literature. *Journal of Neuro-oncology* 102(2): 329-334, 2011.
30. Olteanu H, **Fenske TS**, Harrington AM, Kroft SH. CD23 expression in follicular lymphoma: clinicopathologic correlations. *American Journal of Clinical Pathology* 135(1): 46-53, 2011.
31. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston NW, Carson K, Bartlett NL. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 118(19): 5119-25, 2011.
32. Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theoharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. *Lancet Oncology* 12: 773-84, 2011. [Listed as one of 179 "collaborators," but not as an author].
33. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN. Conditioning

- regimens for allotransplant for diffuse large B-cell lymphoma - myeloablative or reduced intensity? *Blood* 120(20): 4256-62, 2012.
34. *Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, **Fenske TS**, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation*, 19(2): 173-9, 2013.
 35. Hamadani H, Saber W, Ahn KW, Carreras J, Cairo MS, **Fenske TS**, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation* 19(4): 625-31, 2013.
 36. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, **Fenske TS**, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B-cell lymphoma and grade III follicular lymphoma. *Biology of Blood and Marrow Transplantation*, 19(5): 746-53, 2013.
 37. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, **Fenske T**, Horowitz M, Fisher R, Tomblyn M. Phase III randomized study of rituximab/ carmustine, etoposide, cytarabine, melphalan (BEAM) compared with 131-iodine tositumomab/ BEAM with autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 Trial. *Journal of Clinical Oncology* 31(13): 1662-68, 2013.
 38. *Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, **Fenske TS**, Morowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the incidence of engraftment syndrome after transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation* 19(9): 1368-73, 2013.
 39. Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen A, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. Autologous hematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *British Journal of Haematology* 162(5): 648-56, 2013.
 40. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, **Fenske TS**, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *Journal of Clinical Oncology* 31(25): 3100-9, 2013.
 41. **Fenske TS**, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen AF, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg L, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales M, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Montoto S, Maloney DG, Hari PN. Autologous or reduced-intensity allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle cell lymphoma: analysis of transplant timing and modality. *Journal of Clinical Oncology* 32(4): 273-81, 2014.
 42. *Farrington L, Wildes TM, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, **Fenske TS**. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two U.S. academic medical centers. *Therapeutic Advances in Hematology* 5(1): 3-12, 2014.
 43. Wirk B, **Fenske TS**, Hamadani M, Hu Z, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell BJ, Cairo MS, Cashen A, Chen Y, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller ED, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. *Biology of Blood and Marrow Transplantation* 20(7): 951-9, 2014
 44. *Pingali R, Jewell S, Havlat L, Bast M, Thompson J, Eastwood D, Bartlett NL, Armitage JO, Wagner-Johnston N, Vose JM, **Fenske TS**. Limited clinical utility of routine surveillance imaging in classical

- Hodgkin lymphoma patients in first complete remission. *Cancer* 120(14): 2122-9, 2014.
45. Gandhi M, Evens AM, **Fenske TS**, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. *Blood* 123(18): 2895-7, 2014.
 46. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen Y, Costa LJ, **Fenske TS**, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer E, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W. Early failure of frontline rituximab-containing chemoimmunotherapy in diffuse large B-cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 20(11): 1729-36, 2014.
 47. Petrich AM, Gandhi M, Jovanovic B, Castillo J, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan FL, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens A, *Shah NM, **Fenske TS**, Zelenetz A, Landsburg DL, Howlett C, Mato A, Tsai JP, Reddy N, Handler C, Flowers CR, Cohen JB, Blum K, Song K, Sun H, Press O, Cassaday R, Li S, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis. *Blood* 124(15): 2354-61, 2014.
 48. *Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, **Fenske T**, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. *Bone Marrow Transplantation* 50(4): 610-12, 2015.
 49. *Singavi A, *Graff T, Schmidt W, Eastwood D, Drobyski W, Horowitz M, Palmer J, Pasquini M, Rizzo D, Saber W, Hari P, **Fenske TS**. Safety of outpatient autologous hematopoietic cell transplantation (AuHCT) for multiple myeloma and lymphoma. *Bone Marrow Transplantation* 50(7): 947-53, 2015.
 50. *Cornell RF, Zhong X, Arce Lara C, Atallah E, Blust L, Drobyski WR, **Fenske TS**, Pasquini MC, Rizzo JD, Saber W, Hari P. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. *Bone Marrow Transplantation* 50(7): 914-7, 2015.
 51. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL): characteristics, outcomes, and prognostication among a large multicenter cohort. *American Journal of Hematology* 90(9): 778-83, 2015.
 52. **Fenske TS**, *Shah N, Kim K, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo A, Blank JH, Harish A, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS. Weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network phase II study. *Cancer* 121(19): 3465-71, 2015.
 53. Satwani P, Ahn KW, Carreras J, Abdel-Aziz A, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, **Fenske TS**, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DI, Bachanova V, Maloney DG, Sureda A, Smith S, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. *Bone Marrow Transplantation* 50(11): 1416-23, 2015.
 54. *Chandran R, Gardiner SK, **Fenske TS**, Spurgeon ES. Survival trends in T-cell prolymphocytic leukemia: A SEER database analysis. *Leukemia & Lymphoma* 57(4): 942-4, 2016.
 55. Landsburg D, Petrich A, Abramson J, Sohani A, Press O, Cassaday R, Chavez J, Song K, Zelenetz A, Gandhi M, *Shah N, **Fenske T**, Jaso J, Medeiros L, Yang D, Nabhan C. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. *Cancer* 122(4): 559-64, 2016.
 56. Kanate AS, Musetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, **Fenske TS**, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical

- related donors versus HLA-matched unrelated donors. *Blood* 127(7): 938-47, 2016.
57. Alinari L, Gru A, Quinion C, Huang Y, Lozanski G, Poston J, Venkataramn G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Lim HI, Martin P, Cohen JB, Evens A, Al-Mansour Z, *Singavi A, **Fenske TS**, Blum KA. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. *American Journal of Hematology* 91(4): 395-9, 2016.
58. **Fenske TS**, Ahn KW, *Graff TM, Digilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda S, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplant. *British Journal of Haematology*, 174(2): 235-48, 2016.
59. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, **Fenske T**, Longo W, Devine SM, Nadamane A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced intensity conditioning with fludarabine, cyclophosphamide, and high dose Rituxan for allogeneic hematopoietic cell transplantation for follicular lymphoma: A phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN). *Biology of Blood and Marrow Transplantation*, 22(8): 1440-8, 2016.
60. *Dhakal B, D'Souza A, Pasquini M, Saber W, **Fenske TS**, Drobyski W, Moss R, Hari P, Abidi M. DAS181 treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation. *Case Reports in Medicine* 2016 Jan 28 [Epub].
61. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, **Fenske TS**, Ganguly S, Kharfan-Dabaja MA, Prestige TD, Savani BN, Smith SM, Sureda A, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors. *Journal of Clinical Oncology* 34(26): 3141-9, 2016.
62. *Dhakal B, Westfall V, **Fenske TS**, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Watkins K, Pasquini MC, D'Souza AD, Atallah E, Hari P, Kanate AS, Hamadani M. Hematopoietic progenitor cell mobilization with ICE chemotherapy versus plerixafor-based strategies in patients with Hodgkin and non-Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation* 22(10): 1773-80, 2016.
63. *Epperla N, *Kapke JT, *Shah N, Hamadani M, Richardson K, Carrum G, Hari PN, *Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma following autologous hematopoietic cell transplantation. *Clinical Lymphoma, Myeloma & Leukemia* 16(23): 672-678, 2016.
64. *Raj RV, Hari P, Pasquini M, *Epperla N, D'Souza A, **Fenske T**, Shaw BE, Rizzo D, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplantation* 51(12): 1602-04, 2016.
65. *Epperla N, Costa LJ, Maddocks K, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Chavez J, Calzada O, Lansigan F, Nasheed H, Barta S, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri FJ, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, **Fenske TS**, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies. *American Journal of Hematology* 92(2): 161-170, 2017.
66. Chen RW, Li H, Bernstein SH, Kawash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, **Fenske TS**, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG study S1106. *British Journal of Haematology* 176(5):759-769, 2017.
67. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee, JW, Ayala E, Chao N, Hari P, Bolanos-Meade, J, Gress R, Anderson NS, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, **Fenske TS**, Olteanu H. Allogeneic hematopoietic cell transplantation for aggressive NK-cell leukemia: a CIBMTR analysis. *Biology of Blood and Marrow Transplantation* 23(5): 853-56, 2017.
68. *Epperla N, Hamadani H, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabban C, Costa LJ, Kenkre VP, Hari PN, **Fenske TS**. Predictive factors and outcomes for ibrutinib therapy in relapsed / refractory mantle cell lymphoma - a "real world" study. *Hematological Oncology* 2017 Jan 8 [Epub ahead of print].
69. *Epperla N, Dhakal B, **Fenske TS**, Ramalingam S, Shuff J, Hosking P, Rein L, Banerjee A, Hari P, D'Souza

- A, Shah N, Siker M, Erickson-Wittmann BA, Hamadani M. Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies. *Clinical Lymphoma Myeloma and Leukemia* 2017 Feb 16 [Epub ahead of print].
70. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, *Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, **Fenske TS**, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient immune modulation with atorvastatin for acute graft-versus-host disease prophylaxis following allogeneic transplantation. *Biology of Blood and Marrow Transplantation* (in press). 2017 April 12 [Epub ahead of print].
 71. *Epperla N, Hamadani M, **Fenske TS**, Costa LJ. Incidence and survival trends in mantle cell lymphoma. *British Journal of Haematology* 2017 April 25 [Epub ahead of print].
 72. Haverkos BM, Abbott D, Hamadani M, Armande P, Flowers C, Merryman RW, Kamdar M, Kanate AS, Saad A, Mehta M, Ganguly S, **Fenske TS**, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVDH. *Blood* 2017 May 03 [Epub ahead of print].
 73. Landsburg DJ, Falkiewicz, MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Iliazliturri F, Reddy NM, *Singavi A, **Fenske TS**, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of double hit lymphoma patients who achieve first complete remission. *Journal of Clinical Oncology* 2017 May 05 [Epub ahead of print].
 74. *Kapke JT, *Epperla N, *Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, **Fenske TS**. The impact of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma following autologous hematopoietic cell transplantation. *Clinical Lymphoma Myeloma and Leukemia* (in press).
 75. *Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Iliazliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, **Fenske TS**, Hamadani M, Costa L. C-MYC+ relapsed and refractory diffuse large B-cell lymphoma: impact of additional "hits" and outcomes with subsequent therapy. *Cancer* (in press).
 76. Burris HA, Flinn IW, Patel MR, **Fenske TS**, Deng C, Brander DM, Gutierrez M, Essell JH, Savona MR, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, O'Connor OA. TGR-1202, a novel, once-daily PI3K??inhibitor, in relapsed or refractory chronic lymphocytic leukemia and B-cell lymphoma. Submitted.
 77. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, **Fenske TS**, Freytes C, Gaballa S, Ganguly S, Jethava YS, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Sohl M, Sureda A, William B, Cumpston A, Zelenetz A, Link BK, Hamadani M. Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis. Submitted.
 78. Pilchowska M, Pittaluga S, Ferry JA, Hemminger J, Change H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharsi A, Hernandez-Iliazliturri, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM. B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin lymphoma (gray zone lymphoma): a comprehensive clinicopathologic consensus study. Submitted.
 79. *Epperla N, Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Submitted.
 80. *Epperla E, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani A, Smith SM, Sureda A, **Fenske TS**, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing Reduced Intensity Conditioning Reduces the Risk of Therapy Failure following Allogeneic Transplantation in B-cell NHL: A CIBMTR Analysis. Submitted.
 81. Kanate AS, DiGilio A, Ahn KW, Monzr AM, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, **Fenske TS**, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic Hematopoietic Cell Transplantation for Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A CIBMTR Analysis.

- Submitted.
82. *Epperla N, Hohenwarter EJ, Maramattom LV, Rilling WS, **Fenske TS**. Successful yttrium-90 microsphere embolization for hepatic diffuse large B-cell lymphoma refractor to high-dose chemotherapy. Submitted.
 83. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske TS**, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumedil A, Hamadani M, Pasquini M. Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Follicular Lymphoma. A Combined Analysis on Behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Submitted.
 84. *Epperla N, Greenwell B, Staton AS, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilov AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. In preparation.
 85. Dabaja-Kharfan MA, Kumar A, Ayala E, Hamadani M, . . . **Fenske TS** . . . Carpenter P, Savani BN. Practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell lymphomas on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. In preparation.
 86. Vose JM, *Pingali SR, Sehn L, Wagner-Johnson N, **Fenske TS**, Beaven A, Jewell S, Evens A, Kenkre V, Feldman T, Armitage JO. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma in first remission: long-term multicenter analysis in 980 patients. In preparation.
 87. *Dhakal B, **Fenske TS**. Mediastinal gray zone lymphoma with intra-cardiac invasion, before and after chemotherapy. Submitted.
 88. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KC, Hamadani M, **Fenske TS**, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: a large database analysis. In preparation.
 89. *Singavi AK, *Kapke JT, Levin A, Banerjee A, Visotcky A, Zhu F, Hamadani M, Hari PN, **Fenske TS**. Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). In preparation.
 90. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston NW, Carson K, Bartlett NL. A phase II multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. In preparation.
 91. INVITED REVIEWS:
 92. **Fenske TS**, Pengue G, Graubert TA. Dominant negative effects of the AML1/ETO fusion oncoprotein. *Cell Cycle* 4(1): 33-36, 2005.
 93. *Hake CR, Graubert TA, **Fenske TS**. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? *Bone Marrow Transplantation* 39(2): 59-70, 2007.
 94. *Maramattom LV, **Fenske TS**. "Aggressive B-cell Non-Hodgkin Lymphoma," in *Hospital Physician Hematology Board Review Manual* (August 2011), Jacobsen ED (editor).
 95. *Cornell RF, **Fenske TS**. "Indolent B-cell Non-Hodgkin Lymphoma," in *Hospital Physician Hematology Board Review Manual* (October 2011), Jacobsen ED (editor).
 96. Sehn LH, **Fenske TS**, Laport GG. Follicular lymphoma: Prognostic factors, conventional therapies, and hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 18 (1) (Supplement): S82-S91, 2012.
 97. *Pingali SR, **Fenske TS**. "Limited-stage Hodgkin lymphoma," in *Hospital Physician Hematology Board Review Manual*. (August 2012), Jacobsen ED (editor).
 98. *Randhawa J, *Pingali SR, **Fenske TS**. "Advanced-stage and relapsed/refractory Hodgkin lymphoma," in *Hospital Physician Hematology Board Review Manual*. (October 2012), Jacobsen ED (editor).
 99. Klyuchnikov E, Bacher U, *Kroll T, Shea TC, Lazarus H, Bredeson C, **Fenske TS**. Allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma: who, when and how? *Bone Marrow Transplantation*, 49(1): 1-7, 2014.
 100. *Shah N, **Fenske TS**. Post-transplant lymphoproliferative disorders," in *Hospital Physician Hematology Board Review Manual*. (June 2013), Litchkofski, R (editor).
 101. **Fenske TS**. Why is stem cell transplantation so underused in follicular lymphoma? *ASCO Post*, Volume 4, Issue 12 (July 25, 2013).
 102. *Epperla N, **Fenske TS**, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. *World Journal of Transplantation* 5(3):

81-88, 2015.

103. *Epperla N, **Fenske TS**, Lazarus HM, Hamadani M. Post autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? *Bone Marrow Transplantation*, 50(11): 1393-404, 2015.
104. **Fenske TS**, Bredeson C, Hamadani M, Cohen JB, Costa LJ, Kahl B, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. *Biology of Blood and Marrow Transplantation*, 22(9): 1543-51, 2016.
105. Narra R, Pingali SR, **Fenske TS**. "Early stage Hodgkin lymphoma," in *Hospital Physician Hematology Board Review Manual*. (2017), Jacobsen ED (editor). In press.
106. Narra R, Randhawa J, **Fenske TS** "Advanced-stage and relapsed/refractory Hodgkin lymphoma," in *Hospital Physician Hematology Board Review Manual*. (2017), Jacobsen ED (editor). In preparation.
107. **Fenske TS**, Baxter-Lowe LA. Characterization of a novel DQB1 allele associated with HLADQw3: Implications for oligotyping. *Human Immunology* 33: 224-227, 1992.
108. **Fenske TS**, Baxter-Lowe LA. Two novel HLA-DQB1*06 alleles reveal additional heterogeneity of HLA-DQw1. *Tissue Antigens* 40: 49-52, 1992.
109. Farner NL, Gan J, de Jong JLO, Leary TP, **Fenske TS**, Buckley P, Dunlap S, Sondel PM. Alteration of the CD34+ Tf-1b cell line profile in response to long-term exposure to IL-15. *Cytokine* 9 (5): 316-27, 1997.
110. Monson NL, **Fenske TS** (published incorrectly as "**Fenske TJ**"), Wei S, Okragly AJ, de Jong JL, Haak-Frendscho M, O'Shea J, Djeu J, Sondel PM. A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line, Tf-1?2. *Journal of Leukocyte Biology* 69(3):419-25, 2001.
111. **Fenske TS**, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. *Proceedings of the National Academy of Sciences of the United States of America* 101(42): 15184-9, 2004.
112. **Fenske TS**, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, Garry McCoy A, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma. *Leukemia and Lymphoma* 46(10): 1441-8, 2005.
113. **Fenske TS**, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. *Cancer Research* 66(10): 5029-38, 2006.
114. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the Treatment of Patients with Very High-Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy. *Haemophilia* 13(1): 46-50, 2007.
115. **Fenske TS**, *Benjamin H, Kroft SH, Hohenwalter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. *Nature Clinical Practice Oncology* 5(11): 677-81, 2008.
116. *Parker SM, Olteanu H, VanTuinen P, Lawton CA, Schultz CJ, Christians KK, **Fenske TS**. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. *International Journal of Hematology* 90(5): 616-622, 2009.
117. **Fenske TS**, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). *Biology of Blood and Marrow Transplantation* 15(11): 1455-64, 2009.
118. *Kroll T, Ames M, **Fenske TS**. Successful management of pregnancy occurring in a chronic myeloid leukemia patient on dasatinib. *Leukemia and Lymphoma* 51(9): 1-3, 2010.
119. *Torgerson S, *Tinguely M, **Fenske TS**. Intracranial Hodgkin lymphoma: case report and review of the literature. *Journal of Neuro-oncology* 102(2): 329-334, 2011.
120. Olteanu H, **Fenske TS**, Harrington AM, Kroft SH. CD23 expression in follicular lymphoma: clinicopathologic correlations. *American Journal of Clinical Pathology* 135(1): 46-53, 2011.
121. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston NW, Carson K, Bartlett NL. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 118(19): 5119-25, 2011.
122. Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump

- M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. *Lancet Oncology* 12: 773-84, 2011. [Listed as one of 179 "collaborators," but not as an author].
123. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN. Conditioning regimens for allotransplant for diffuse large B-cell lymphoma - myeloablative or reduced intensity? *Blood* 120(20): 4256-62, 2012.
124. *Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, **Fenske TS**, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation*, 19(2): 173-9, 2013.
125. Hamadani H, Saber W, Ahn KW, Carreras J, Cairo MS, **Fenske TS**, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation* 19(4): 625-31, 2013.
126. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, **Fenske TS**, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B-cell lymphoma and grade III follicular lymphoma. *Biology of Blood and Marrow Transplantation*, 19(5): 746-53, 2013.
127. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, **Fenske T**, Horowitz M, Fisher R, Tomblyn M. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, melphalan (BEAM) compared with 131-iodine tositumomab/BEAM with autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 Trial. *Journal of Clinical Oncology* 31(13): 1662-68, 2013.
128. *Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, **Fenske TS**, Morowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the incidence of engraftment syndrome after transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation* 19(9): 1368-73, 2013.
129. Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen A, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. Autologous hematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *British Journal of Haematology* 162(5): 648-56, 2013.
130. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, **Fenske TS**, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *Journal of Clinical Oncology* 31(25): 3100-9, 2013.
131. **Fenske TS**, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen AF, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg L, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales M, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Montoto S, Maloney DG, Hari PN. Autologous or reduced-intensity allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle cell lymphoma: analysis of transplant timing and modality. *Journal of Clinical Oncology* 32(4): 273-81, 2014.
132. *Farrington L, Wildes TM, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, **Fenske TS**. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two U.S. academic medical centers. *Therapeutic Advances in Hematology* 5(1): 3-12, 2014.
133. Wirk B, **Fenske TS**, Hamadani M, Hu Z, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell BJ, Cairo MS, Cashen A, Chen Y, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA,

- Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller ED, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. *Biology of Blood and Marrow Transplantation* 20(7): 951-9, 2014
134. *Pingali R, Jewell S, Havlat L, Bast M, Thompson J, Eastwood D, Bartlett NL, Armitage JO, Wagner-Johnston N, Vose JM, **Fenske TS**. Limited clinical utility of routine surveillance imaging in classical Hodgkin lymphoma patients in first complete remission. *Cancer* 120(14): 2122-9, 2014.
135. Gandhi M, Evens AM, **Fenske TS**, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. *Blood* 123(18): 2895-7, 2014.
136. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen Y, Costa LJ, **Fenske TS**, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer E, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W. Early failure of frontline rituximab-containing chemoimmunotherapy in diffuse large B-cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 20(11): 1729-36, 2014.
137. Petrich AM, Gandhi M, Jovanovic B, Castillo J, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan FL, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens A, *Shah NM, **Fenske TS**, Zelenetz A, Landsburg DL, Howlett C, Mato A, Tsai JP, Reddy N, Handler C, Flowers CR, Cohen JB, Blum K, Song K, Sun H, Press O, Cassaday R, Li S, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis. *Blood* 124(15): 2354-61, 2014.
138. *Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, **Fenske T**, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. *Bone Marrow Transplantation* 50(4): 610-12, 2015.
139. *Singavi A, *Graff T, Schmidt W, Eastwood D, Drobyski W, Horowitz M, Palmer J, Pasquini M, Rizzo D, Saber W, Hari P, **Fenske TS**. Safety of outpatient autologous hematopoietic cell transplantation (AuHCT) for multiple myeloma and lymphoma. *Bone Marrow Transplantation* 50(7): 947-53, 2015.
140. *Cornell RF, Zhong X, Arce Lara C, Atallah E, Blust L, Drobyski WR, **Fenske TS**, Pasquini MC, Rizzo JD, Saber W, Hari P. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. *Bone Marrow Transplantation* 50(7): 914-7, 2015.
141. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL): characteristics, outcomes, and prognostication among a large multicenter cohort. *American Journal of Hematology* 90(9): 778-83, 2015.
142. **Fenske TS**, *Shah N, Kim K, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo A, Blank JH, Harish A, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS. Weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network phase II study. *Cancer* 121(19): 3465-71, 2015.
143. Satwani P, Ahn KW, Carreras J, Abdel-Azim A, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, **Fenske TS**, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DI, Bachanova V, Maloney DG, Sureda A, Smith S, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. *Bone Marrow Transplantation* 50(11): 1416-23, 2015.
144. *Chandran R, Gardiner SK, **Fenske TS**, Spurgeon ES. Survival trends in T-cell prolymphocytic leukemia: A SEER database analysis. *Leukemia & Lymphoma* 57(4): 942-4, 2016.
145. Landsburg D, Petrich A, Abramson J, Sohani A, Press O, Cassaday R, Chavez J, Song K, Zelenetz A,

- Gandhi M, *Shah N, **Fenske T**, Jaso J, Medeiros L, Yang D, Nabhan C. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. *Cancer* 122(4): 559-64, 2016.
146. Kanate AS, Musetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, **Fenske TS**, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. *Blood* 127(7): 938-47, 2016.
147. Alinari L, Gru A, Quinion C, Huang Y, Lozanski G, Poston J, Venkataramn G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Lim HI, Martin P, Cohen JB, Evens A, Al-Mansour Z, *Singavi A, **Fenske TS**, Blum KA. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. *American Journal of Hematology* 91(4): 395-9, 2016.
148. **Fenske TS**, Ahn KW, *Graff TM, Digilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda S, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplant. *British Journal of Haematology*, 174(2): 235-48, 2016.
149. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, **Fenske T**, Longo W, Devine SM, Nadamane A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced intensity conditioning with fludarabine, cyclophosphamide, and high dose Rituxan for allogeneic hematopoietic cell transplantation for follicular lymphoma: A phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN). *Biology of Blood and Marrow Transplantation*, 22(8): 1440-8, 2016.
150. *Dhakal B, D'Souza A, Pasquini M, Saber W, **Fenske TS**, Drobyski W, Moss R, Hari P, Abidi M. DAS181 treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation. *Case Reports in Medicine* 2016 Jan 28 [Epub].
151. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, **Fenske TS**, Ganguly S, Kharfan-Dabaja MA, Prestige TD, Savani BN, Smith SM, Sureda A, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors. *Journal of Clinical Oncology* 34(26): 3141-9, 2016.
152. *Dhakal B, Westfall V, **Fenske TS**, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Watkins K, Pasquini MC, D'Souza AD, Atallah E, Hari P, Kanate AS, Hamadani M. Hematopoietic progenitor cell mobilization with ICE chemotherapy versus plerixafor-based strategies in patients with Hodgkin and non-Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation* 22(10): 1773-80, 2016.
153. *Epperla N, *Kapke JT, *Shah N, Hamadani M, Richardson K, Carrum G, Hari PN, *Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma following autologous hematopoietic cell transplantation. *Clinical Lymphoma, Myeloma & Leukemia* 16(23): 672-678, 2016.
154. *Raj RV, Hari P, Pasquini M, *Epperla N, D'Souza A, **Fenske T**, Shaw BE, Rizzo D, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplantation* 51(12): 1602-04, 2016.
155. *Epperla N, Costa LJ, Maddocks K, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Chavez J, Calzada O, Lansigan F, Nasheed H, Barta S, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri FJ, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, **Fenske TS**, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies. *American Journal of Hematology* 92(2): 161-170, 2017.
156. Chen RW, Li H, Bernstein SH, Kawash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, **Fenske TS**, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG study S1106. *British Journal of Haematology* 176(5):759-769, 2017.
157. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee, JW, Ayala E, Chao N, Hari P, Bolanos-

- Meade, J, Gress R, Anderson NS, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, **Fenske TS**, Olteanu H. Allogeneic hematopoietic cell transplantation for aggressive NK-cell leukemia: a CIBMTR analysis. *Biology of Blood and Marrow Transplantation* 23(5): 853-56, 2017.
158. *Epperla N, Hamadani H, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabban C, Costa LJ, Kenkre VP, Hari PN, **Fenske TS**. Predictive factors and outcomes for ibrutinib therapy in relapsed / refractory mantle cell lymphoma - a "real world" study. *Hematological Oncology* 2017 Jan 8 [Epub ahead of print].
159. *Epperla N, Dhakal B, **Fenske TS**, Ramalingam S, Shuff J, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Erickson-Wittmann BA, Hamadani M. Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies. *Clinical Lymphoma Myeloma and Leukemia* 2017 Feb 16 [Epub ahead of print].
160. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, *Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, **Fenske TS**, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient immune modulation with atorvastatin for acute graft-versus-host disease prophylaxis following allogeneic transplantation. *Biology of Blood and Marrow Transplantation* (in press). 2017 April 12 [Epub ahead of print].
161. *Epperla N, Hamadani M, **Fenske TS**, Costa LJ. Incidence and survival trends in mantle cell lymphoma. *British Journal of Haematology* 2017 April 25 [Epub ahead of print].
162. Haverkos BM, Abbott D, Hamadani M, Armande P, Flowers C, Merryman RW, Kamdar M, Kanate AS, Saad A, Mehta M, Ganguly S, **Fenske TS**, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVDH. *Blood* 2017 May 03 [Epub ahead of print].
163. Landsburg DJ, Falkiewicz, MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, *Singavi A, **Fenske TS**, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of double hit lymphoma patients who achieve first complete remission. *Journal of Clinical Oncology* 2017 May 05 [Epub ahead of print].
164. *Kapke JT, *Epperla N, *Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, **Fenske TS**. The impact of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma following autologous hematopoietic cell transplantation. *Clinical Lymphoma Myeloma and Leukemia* (in press).
165. *Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, **Fenske TS**, Hamadani M, Costa L. C-MYC+ relapsed and refractory diffuse large B-cell lymphoma: impact of additional "hits" and outcomes with subsequent therapy. *Cancer* (in press).
166. Burris HA, Flinn IW, Patel MR, **Fenske TS**, Deng C, Brander DM, Gutierrez M, Essell JH, Savona MR, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, O'Connor OA. TGR-1202, a novel, once-daily PI3K??inhibitor, in relapsed or refractory chronic lymphocytic leukemia and B-cell lymphoma. Submitted.
167. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, **Fenske TS**, Freytes C, Gaballa S, Ganguly S, Jethava YS, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Sohl M, Sureda A, William B, Cumpston A, Zelenetz A, Link BK, Hamadani M. Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis. Submitted.
168. Pilchowska M, Pittaluga S, Ferry JA, Hemminger J, Change H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharsi A, Hernandez-Ilizaliturri, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM. B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin lymphoma (gray zone lymphoma): a comprehensive clinicopathologic consensus study. Submitted.
169. *Epperla N, Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Submitted.
170. *Epperla E, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani A,

- Smith SM, Sureda A, **Fenske TS**, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing Reduced Intensity Conditioning Reduces the Risk of Therapy Failure following Allogeneic Transplantation in B-cell NHL: A CIBMTR Analysis. Submitted.
171. Kanate AS, DiGilio A, Ahn KW, Monzr AM, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, **Fenske TS**, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic Hematopoietic Cell Transplantation for Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A CIBMTR Analysis. Submitted.
 172. *Epperla N, Hohenwarter EJ, Maramattom LV, Rilling WS, **Fenske TS**. Successful yttrium-90 microsphere embolization for hepatic diffuse large B-cell lymphoma refractor to high-dose chemotherapy. Submitted.
 173. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske TS**, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumedil A, Hamadani M, Pasquini M. Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Follicular Lymphoma. A Combined Analysis on Behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Submitted.
 174. *Epperla N, Greenwell B, Staton AS, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilov AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. In preparation.
 175. Dabaja-Kharfan MA, Kumar A, Ayala E, Hamadani M, . . . **Fenske TS** . . . Carpenter P, Savani BN. Practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell lymphomas on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. In preparation.
 176. Vose JM, *Pingali SR, Sehn L, Wagner-Johnson N, **Fenske TS**, Beaven A, Jewell S, Evens A, Kenkre V, Feldman T, Armitage JO. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma in first remission: long-term multicenter analysis in 980 patients. In preparation.
 177. *Dhakal B, **Fenske TS**. Mediastinal gray zone lymphoma with intra-cardiac invasion, before and after chemotherapy. Submitted.
 178. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KC, Hamadani M, **Fenske TS**, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: a large database analysis. In preparation.
 179. *Singavi AK, *Kapke JT, Levin A, Banerjee A, Visotcky A, Zhu F, Hamadani M, Hari PN, **Fenske TS**. Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). In preparation.
 180. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston NW, Carson K, Bartlett NL. A phase II multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. In preparation.
 181. INVITED REVIEWS:
 182. **Fenske TS**, Pengue G, Graubert TA. Dominant negative effects of the AML1/ETO fusion oncoprotein. *Cell Cycle* 4(1): 33-36, 2005.
 183. *Hake CR, Graubert TA, **Fenske TS**. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? *Bone Marrow Transplantation* 39(2): 59-70, 2007.
 184. *Maramattom LV, **Fenske TS**. "Aggressive B-cell Non-Hodgkin Lymphoma," in *Hospital Physician Hematology Board Review Manual* (August 2011), Jacobsen ED (editor).
 185. *Cornell RF, **Fenske TS**. "Indolent B-cell Non-Hodgkin Lymphoma," in *Hospital Physician Hematology Board Review Manual* (October 2011), Jacobsen ED (editor).
 186. Sehn LH, **Fenske TS**, Laport GG. Follicular lymphoma: Prognostic factors, conventional therapies, and hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 18 (1) (Supplement): S82-S91, 2012.
 187. *Pingali SR, **Fenske TS**. "Limited-stage Hodgkin lymphoma," in *Hospital Physician Hematology Board Review Manual*. (August 2012), Jacobsen ED (editor).
 188. *Randhawa J, *Pingali SR, **Fenske TS**. "Advanced-stage and relapsed/refractory Hodgkin lymphoma," in *Hospital Physician Hematology Board Review Manual*. (October 2012), Jacobsen ED (editor).
 189. Klyuchnikov E, Bacher U, *Kroll T, Shea TC, Lazarus H, Bredeson C, **Fenske TS**. Allogeneic

- hematopoietic cell transplantation for diffuse large B-cell lymphoma: who, when and how? Bone Marrow Transplantation, 49(1): 1-7, 2014.
190. *Shah N, **Fenske TS**. Post-transplant lymphoproliferative disorders," in Hospital Physician Hematology Board Review Manual. (June 2013), Litchkofski, R (editor).
 191. **Fenske TS**. Why is stem cell transplantation so underused in follicular lymphoma? ASCO Post, Volume 4, Issue 12 (July 25, 2013).
 192. *Epperla N, **Fenske TS**, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World Journal of Transplantation 5(3): 81-88, 2015.
 193. *Epperla N, **Fenske TS**, Lazarus HM, Hamadani M. Post autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplantation, 50(11): 1393-404, 2015.
 194. **Fenske TS**, Bredeson C, Hamadani M, Cohen JB, Costa LJ, Kahl B, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. Biology of Blood and Marrow Transplantation, 22(9): 1543-51, 2016.
 195. Narra R, Pingali SR, **Fenske TS**. "Early stage Hodgkin lymphoma," in Hospital Physician Hematology Board Review Manual. (2017), Jacobsen ED (editor). In press.
 196. Narra R, Randhawa J, **Fenske TS** "Advanced-stage and relapsed/refractory Hodgkin lymphoma," in Hospital Physician Hematology Board Review Manual. (2017), Jacobsen ED (editor). In preparation.

Books, Chapters, and Reviews

1. **Fenske TS**, Bartlett NL. "Lymphoma of the Mediastinum," in Pearson's Thoracic and Esophageal Surgery, 3rd edition, Patterson GA, Pearson FG, Cooper JD, Deslauriers J, Rice TW, Luketich JD, Lerut A (editors), 2008.
2. **Fenske TS**, Bartlett NL. "Lymphoma of the Mediastinum," in Pearson's Thoracic and Esophageal Surgery, 3rd edition, Patterson GA, Pearson FG, Cooper JD, Deslauriers J, Rice TW, Luketich JD, Lerut A (editors), 2008.
3. *Singavi A, Harrington A, **Fenske TS**. "Post Transplant Lymphoproliferative Disorders," in Cancer Treatment and Research: Non-Hodgkin Lymphoma. Evens A, Blum K (editors), Volume 165, pp 305-327, 2014.
4. *Pingali SR, **Fenske TS**. "Hematopoietic Cell Transplantation in Mantle Cell Lymphoma." In Hematopoietic Cell Transplants: Concepts, Controversies and Future Directions, Lazarus H, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, and Abutalib SA (editors), 2016. In press.
5. *Epperla N, **Fenske TS**. "Hematopoietic Cell Transplantation in Mantle Cell Lymphoma" In Blood & Bone Marrow Transplantation: Expert Clinical Manual, Abutalib SA and Hari P (editors), 2017. In press.
6. *Kapke JT and **Fenske TS**. "Aggressive Lymphomas" in Concise Guide to Hematology, Lazarus H and Schmaier AH (editors), 2017. In preparation.
7. **Fenske TS**, Bartlett NL. "Lymphoma of the Mediastinum," in Pearson's Thoracic and Esophageal Surgery, 3rd edition, Patterson GA, Pearson FG, Cooper JD, Deslauriers J, Rice TW, Luketich JD, Lerut A (editors), 2008.
8. *Singavi A, Harrington A, **Fenske TS**. "Post Transplant Lymphoproliferative Disorders," in Cancer Treatment and Research: Non-Hodgkin Lymphoma. Evens A, Blum K (editors), Volume 165, pp 305-327, 2014.
9. *Pingali SR, **Fenske TS**. "Hematopoietic Cell Transplantation in Mantle Cell Lymphoma." In Hematopoietic Cell Transplants: Concepts, Controversies and Future Directions, Lazarus H, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, and Abutalib SA (editors), 2016. In press.
10. *Epperla N, **Fenske TS**. "Hematopoietic Cell Transplantation in Mantle Cell Lymphoma" In Blood & Bone Marrow Transplantation: Expert Clinical Manual, Abutalib SA and Hari P (editors), 2017. In press.
11. *Kapke JT and **Fenske TS**. "Aggressive Lymphomas" in Concise Guide to Hematology, Lazarus H and Schmaier AH (editors), 2017. In preparation.

Abstracts

1. **Fenske TS**, Majewski DM, Baxter-Lowe LA. Use of oligotyping to detect novel HLA-DQ alleles and to assess linkage disequilibrium between HLA-DQA1 and HLA-DQB1 alleles. Human Immunology 34 (suppl 1): 20, 1992. 1992 American Assn. of Immunology Annual Meeting (Minneapolis, MN).
2. **Fenske TS**, Farmer NL, de Jong JLO, O'Shea JJ, Sondel PM. Interleukin-2 mediated activation of JAK3 in the absence of a detectable 64 kDa common gamma chain. FASEB Journal 10 (6): A1303, 1996. 1996 FASEB/ASBMB Annual Meeting. (New Orleans, LA - selected for oral presentation, given by T.

- Fenske).
3. **Fenske TS**. Bilateral leg pain and weakness in a patient with polycythemia vera. American College of Physicians / American Society of Internal Medicine, Wisconsin Chapter, Annual Meeting, Sept 2001. (Milwaukee, WI - Poster and oral presentation, given by T. Fenske).
 4. **Fenske TS**, Kahl BS, Smith EP, Atkinson E, Garry-McCoy A, Mitchell TL, Eckstein L, Flynn B, McMannes J, Eickhoff J, Longo WL. High dose therapy with thioetpa, etoposide, total body irradiation and involved field radiation followed by autologous stem cell rescue for indolent histology and mantle cell non-Hodgkin lymphoma. 2002 ASH Annual Meeting, Abstract 5461 (Philadelphia, PA).
 5. **Fenske TS**, Mathews V, Pengue G, Hanson P, Bogue M, McLeod HL, Graubert TA. Genetic basis of susceptibility to alkylator chemotherapy-related leukemia. 2003 ASH Annual Meeting, Abstract 1348. (San Diego, CA - selected for poster session, presented by T. Fenske).
 6. Pengue G, Mathews V, **Fenske T**, Hanson P, Marrus S, Riaz N, Graubert TA. Targeting AML1-ETO to the hematopoietic stem cell compartment induces myeloproliferative disease in mice. 2003 ASH Annual Meeting, Abstract 756. (San Diego, CA - selected for oral presentation, given by T. Fenske).
 7. Devine SM, Hallemeier C, **Fenske T**, Vij R, DiPersio JF, Adkins DA. Reduced intensity allografts for acute myeloid leukemia: defining the role of conditioning and donor alloreactivity. 2004 ASH Annual Meeting (San Diego, CA).
 8. Edwin D, McMahan C, Kreisel F, Bogue M, **Fenske TS**, Graubert TA. A mouse model of alkylator-induced myelodysplastic syndrome. 2005 American Society of Hematology Annual Meeting (Atlanta, GA - oral presentation).
 9. Edwin D, **Fenske TS**, McMahan C, Mathews V, Bogue M, Province M, Cheverud J, McLeod H, Graubert TA. Susceptibility to alkylator-induced cancer is a heritable trait. 2005 American Society of Hematology Annual Meeting (Atlanta, GA - poster).
 10. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the treatment of high titer acquired factor VIII inhibitors refractory to conventional chemotherapy. 2005 American Society of Hematology Annual Meeting (Atlanta, GA - poster).
 11. Benjamin H, **Fenske TS**, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. 2007 American Society of Hematology Annual Meeting (Atlanta, GA).
 12. **Fenske TS**, Hari P, Carreras J, Zhang M, Kamble R, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Pre-transplant rituximab therapy is associated with improved progression-free and overall survival in patients undergoing autologous stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). 2007 American Society of Hematology Annual Meeting (Atlanta, GA - selected for oral presentation, given by T. Fenske).
 13. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, DiPersio JF, Bartlett NL. A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. 2009 American Society of Hematology Annual Meeting (New Orleans, LA).
 14. Randhawa J, Bredeson C, **Fenske T**, Hari P, Palmer J, Saad A, Olteanu H, Atallah E. Outpatient Hypomethylating therapy for acute myelogenous leukemia (AML) can induce sustained responses with low induction mortality. 2009 American Society of Hematology Annual Meeting (New Orleans, LA).
 15. Connelly J, Harrington A, Kroft S, Ho K, **Fenske T**, Malkin M. Methotrexate-induced CNS Hodgkin-like lymphoproliferative disorder: a case report. 2009 Joint Meeting of the Society for NeuroOncology and the American Association of Neurological Surgeons / Congress of Neurological Surgeons (New Orleans, LA).
 16. Hari P, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, **Fenske TS**. Allogeneic transplantation (AlloHCT) for patients with mantle cell lymphoma (MCL) progressing after autologous transplantation (AutoHCT). 2011 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 17. **Fenske TS**, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, Hari P. Outcomes of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. 2011 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 18. Vose JM, Carter SL, Burns L, Ayala E, Press O, Moskowitz C, Stadtmauer E, Mineshi S, Ambinder R, **Fenske T**, Difronzo N, Horowitz M, Tomblyn M. Randomized phase III trial of 131 Iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). 2011 American Society of Hematology Annual Meeting (San Diego, CA).

19. Cornell RF, Thompson J, Drobyski WR, **Fenske TS**, Horowitz MM, Palmer JM, Pasquini MC, Saad AA, Rizzo JD, Saber W, Zhang MJ, Zhong X, Hari P. Risk factors and clinical features of autologous graft-versus-host disease/ engraftment syndrome after autologous hematopoietic cell (HCT) transplantation. 2012 Tandem BMT Meetings (San Diego CA).
20. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, **Fenske TS**, Cashen AF, Wagner-Johnston N, Carson K, Bartlett NL. A phase II multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. 2012 American Society of Hematology Annual Meeting (Atlanta, GA).
21. Chang JE, Zhang C, Kim K, Kirby R, Volk L, Wernkli J, Go R, Weiss M, Blank J, Farnen J, Cole C, Bseiso A, Volk M, Bayer G, Traynor A, Mansky P, **Fenske TS**, Kahl BS. Bendamustine + rituximab (BR) chemoimmunotherapy and maintenance lenalidomide in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): A Wisconsin Oncology Network (WON) Study. 2012 American Society of Hematology Annual Meeting (Atlanta, GA).
22. Schmidt S, Blust L, Knudson P, Richter E, Palmer J, **Fenske T**, Eastwood D, Zhang M, Atallah E. The effect of hyperglycemia on the outcome of patients with acute myelogenous leukemia. 2012 American Society of Hematology Annual Meeting (Atlanta, GA).
23. **Fenske TS**, Majewski DM, Baxter-Lowe LA. Use of oligotyping to detect novel HLA-DQ alleles and to assess linkage disequilibrium between HLA-DQA1 and HLA-DQB1 alleles. *Human Immunology* 34 (suppl 1): 20, 1992. 1992 American Association of Immunology Meeting (Minneapolis, MN).
24. **Fenske TS**, Farner NL, de Jong JLO, O'Shea JJ, Sondel PM. Interleukin-2 mediated activation of JAK3 in the absence of a detectable 64 kDa common gamma chain. *FASEB Journal* 10 (6): A1303, 1996. 1996 FASEB/ASBMB Annual Meeting. (New Orleans, LA).
25. **Fenske TS**. Bilateral leg pain and weakness in a patient with polycythemia vera. American College of Physicians/ American Society of Internal Medicine, Wisconsin Chapter, Annual Meeting, Sept 2001. (Milwaukee, WI).
26. **Fenske TS**, Kahl BS, Smith EP, Atkinson E, Garry-McCoy A, Mitchell TL, Eckstein L, Flynn B, McMannes J, Eickhoff J, Longo WL. High dose therapy with thioetpa, etoposide, total body irradiation and involved field radiation followed by autologous stem cell rescue for indolent histology and mantle cell non-Hodgkin lymphoma. 2002 ASH Meeting, Abstract 5461 (Philadelphia, PA).
27. **Fenske TS**, Mathews V, Pengue G, Hanson P, Bogue M, McLeod HL, Graubert TA. Genetic basis of susceptibility to alkylator chemotherapy-related leukemia. 2003 ASH Meeting, Abstract 1348 Oral Presentation (San Diego, CA).
28. Pengue G, Mathews V, **Fenske T**, Hanson P, Marrus S, Riaz N, Graubert TA. Targeting AML1-ETO to the hematopoietic stem cell compartment induces myeloproliferative disease in mice. 2003 American Society of Hematology Meeting, Abstract 756, Oral Presentation (San Diego, CA).
29. Devine SM, Hallemeier C, **Fenske T**, Vij R, DiPersio JF, Adkins DA. Reduced intensity allografts for acute myeloid leukemia: defining the role of conditioning and donor alloreactivity. 2004 American Society of Hematology Meeting (San Diego, CA).
30. Edwin D, McMahon C, Kreisel F, Bogue M, **Fenske TS**, Graubert TA. A mouse model of alkylator-induced myelodysplastic syndrome. 2005 American Society of Hematology Meeting, Oral Presentation (Atlanta, GA).
31. Edwin D, **Fenske TS**, McMahon C, Mathews V, Bogue M, Province M, Cheverud J, McLeod H, Graubert TA. Susceptibility to alkylator-induced cancer is a heritable trait. 2005 American Society of Hematology Meeting, Poster (Atlanta, GA).
32. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the treatment of high titer acquired factor VIII inhibitors refractory to conventional chemotherapy. 2005 American Society of Hematology Meeting, Poster (Atlanta, GA).
33. *Benjamin H, **Fenske TS**, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. 2007 American Society of Hematology Meeting (Atlanta, GA).
34. **Fenske TS**, Hari P, Carreras J, Zhang M, Kamble R, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Pre-transplant rituximab therapy is associated with improved progression-free and overall survival in patients undergoing autologous stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). 2007 American Society of Hematology Meeting, Oral Presentation (Atlanta, GA).
35. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, DiPersio JF, Bartlett NL. A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. 2009 American Society of Hematology Meeting (New Orleans, LA).

36. *Randhawa J, Bredeson C, **Fenske T**, Hari P, Palmer J, Saad A, Olteanu H, Atallah E. Outpatient Hypomethylating therapy for acute myelogenous leukemia (AML) can induce sustained responses with low induction mortality. 2009 American Society of Hematology Meeting (New Orleans, LA).
37. Connelly J, Harrington A, Kroft S, Ho K, **Fenske T**, Malkin M. Methotrexate-induced CNS Hodgkin-like lymphoproliferative disorder: a case report. 2009 Joint Meeting of the Society for NeuroOncology and the American Association of Neurological Surgeons / Congress of Neurological Surgeons (New Orleans, LA).
38. Hari P, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, **Fenske TS**. Allogeneic transplantation (AlloHCT) for patients with mantle cell lymphoma (MCL) progressing after autologous transplantation (AutoHCT). 2011 International Conference on Malignant Lymphoma, Oral Presentation (Lugano, Switzerland).
39. **Fenske TS**, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, Hari P. Outcomes of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. 2011 International Conference on Malignant Lymphoma, Oral Presentation (Lugano, Switzerland).
40. Vose JM, Carter SL, Burns L, Ayala E, Press O, Moskowitz C, Stadtmauer E, Mineshi S, Ambinder R, **Fenske T**, Difronzo N, Horowitz M, Tomblyn M. Randomized phase III trial of 131 Iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). 2011 American Society of Hematology Meeting, Oral Presentation (San Diego, CA).
41. *Cornell RF, Thompson J, Drobyski WR, **Fenske TS**, Horowitz MM, Palmer JM, Pasquini MC, Saad AA, Rizzo JD, Saber W, Zhang MJ, Zhong X, Hari P. Risk factors and clinical features of autologous graft-versus-host disease/ engraftment syndrome after autologous hematopoietic cell (HCT) transplantation. 2012 Tandem BMT Meetings (San Diego CA).
42. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, **Fenske TS**, Cashen AF, Wagner-Johnston N, Carson K, Bartlett NL. A phase II multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. 2012 American Society of Hematology Meeting (Atlanta, GA).
43. Chang JE, Zhang C, Kim K, Kirby R, Volk L, Werndli J, Go R, Weiss M, Blank J, Farnen J, Cole C, Bseiso A, Volk M, Bayer G, Traynor A, Mansky P, **Fenske TS**, Kahl BS. Bendamustine + rituximab (BR) chemoimmunotherapy and maintenance lenalidomide in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): A Wisconsin Oncology Network (WON) Study. 2012 American Society of Hematology Meeting (Atlanta, GA).
44. Wirk B, Burns L, **Fenske TS**, Hu Z, Laport G, Montoto S, Maloney D, Saber W. Clinical outcomes of hematopoietic cell transplantation in patients with diffuse large B cell lymphoma transformed from follicular lymphoma. 2013 Tandem BMT Meetings, Oral Presentation (Salt Lake City, UT).
45. *Xia C, Zhong X, Dhokal B, Thompson J, **Fenske T**, Esselmann J, Keever-Taylor C, Padmanabhan A, Hari P. Plerixafor overcomes the adverse effect of diabetes on hematopoietic progenitor cell mobilization. 2013 Tandem BMT Meetings (Salt Lake City, UT).
46. Hintzke M, **Fenske T**, Kroft SH, Olteanu O, Harrington AM. CD30 expression in non-Hodgkin B-cell lymphoma. 2013 United States & Canadian Academy of Pathology Annual Meeting (Baltimore, MD).
47. *Cornell RF, *Randhawa JK, Drobyski W, Zhong X, *Thompson J, Horowitz MM, **Fenske T**, Palmer J, Pasquini MC, Saber W, Thomas M, Zhang M, Hari PN. Risk factors and clinical features of engraftment syndrome after autologous hematopoietic cell transplantation (AHCT). 2013 Tandem BMT Meetings, Oral Presentation, (Salt Lake City, UT).
48. *Giever TA, Richter EL, Broge KM, Foy PC, Blust LS, Palmer JM, **Fenske TS**, Rilling WS, Hari P, Atallah EL. High incidence of venous thromboembolism in patients with hematological malignancies related to upper extremity peripherally inserted central venous catheters. 2013 American Society of Clinical Oncology Meeting, Poster (Chicago, IL).
49. *Pingali R, Jewell S, Bast M, Thompson J, Eastwood D, Bartlett NL, Armitage JO, Wagner-Johnston N, Vose JM, **Fenske TS**. Clinical or survival benefit to routine surveillance imaging in classical Hodgkin lymphoma patients in first complete remission. 2013 American Society of Clinical Oncology Meeting, Oral Presentation (Chicago, IL).
50. Evens AM, Hamlin PA, Advani RH, Fanale M, Smith SM, Bociek G, **Fenske TS**, Petrich A, Winter J, Gordon L. Sequential brentuximab vedotin (BV) with adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma: preliminary toxicity findings from a phase II window study. 2013 International Symposium on Hodgkin Lymphoma (Cologne, Germany).

51. Gandhi MD, Petrich AM, Cassady R, Press O, Shah KA, Whyman JD, Lansigan F, Zelenetz A, *Shah N, **Fenske T**, Hernandez-Ilizaliturri FJ, Lee JX, Barta SK, Karmali R, Camille A, Smith S, Vose J, Dalal N, Nabhan C, Peace D, Jovanovic B, Sohani A, Evens A, Castillo J, Abramson JS. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): A large multicenter retrospective analysis. 2013 American Society of Hematology Meeting, Oral Presentation (New Orleans, GA).
52. **Fenske TS**, Kim K, Zhang C, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor A, Mattison RJ, Kahl BS. Weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network Phase II study. 2013 American Society of Hematology Meeting, Poster (New Orleans, GA).
53. Gandhi M, Evens A, **Fenske TS**, Hamlin P, Coiffier B, Ghosh N, Moskowitz A, Petrich A, Engert A, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio S, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event. 2013 American Society of Hematology Meeting (New Orleans, GA).
54. *Pingali R, Vose JM, Wagner-Johnson N, Loberiza FR, **Fenske TS**, Jewell S, Bast M, Bartlett NL, Armitage JO. Lack of clinical benefit for routine surveillance imaging for diffuse large B-cell lymphoma in first complete remission. 2013 American Society of Hematology Meeting, Poster (New Orleans, GA).
55. *Graff T, *Singavi A, Schmidt W, Eastwood D, Drobyski W, Horowitz M, Palmer J, Pasquini M, Rizzo D, Saber W, Hari P, **Fenske TS**. Safety of outpatient autologous hematopoietic cell transplantation (AuHCT) for multiple myeloma and lymphoma. 2014 Tandem BMT Meetings (Dallas, TX).
56. *Peswani N, Carlson KS, Chitambar CR, **Fenske TS**, Hari P, Michaelis L, Blust LS, Atallah H. Short time to ATRA administration and reduction of early mortality in patients with APL. 2014 American Society of Clinical Oncology Meeting (Chicago, IL).
57. *Chandran R, Gardiner SK, **Fenske TS**, Spurgeon SE. Survival trends in T cell prolymphocytic leukemia: a SEER database analysis. 2014 Ultmann Chicago Lymphoma Symposium (Chicago, IL).
58. *Peswani N, **Fenske T**, Hari P, Carlson KS, Michaelis L, Chitambar C, Baumann-Kreuziger L, Atallah E. D-dimer kinetics, chemotherapy and the risk of bleeding in patients with acute promyelocytic leukemia. 2014 World Congress on Controversies in Thrombosis and Hemostasis (Berlin, Germany).
59. Burris HA, Patel MR, Brander D, O'Connor OA, Deng C, **Fenske TS**, Gutierrez M, Jones SF, Kuhn JG, Miskin HP, Sportelli P, Vakkalank S, Flinn I. TGR-1202 a novel once daily PI3K γ inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. 2014 American Society of Hematology Meeting (San Francisco, CA).
60. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, **Fenske T**, Longo W, Devine SM, Nadamane A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced intensity conditioning (RIC) with rituximab yields excellent outcomes after allogeneic hematopoietic cell transplantation (alloHCT) for relapsed follicular lymphoma (FL): A phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN). 2014 American Society of Hematology Meeting (San Francisco, CA).
61. Kritharis A, Kanakry JA, Sehn LH, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Lossos IS, Press OW, **Fenske T**, Friedberg JW, Vose JM, Blum KA, Evens AM. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL): analysis of tumor immunophenotype and critical examination of therapy with associated impact on outcome. 2014 American Society of Hematology Meeting (San Francisco, CA).
62. *Peswani N, Baumann-Kreuziger L, Carlson K, Michaelis L, Hari P, **Fenske T**, Chitambar C, Atallah E. D-dimer kinetics, chemotherapy, and the risk of bleeding in acute promyelocytic leukemia. 2014 American Society of Hematology Meeting (San Francisco, CA).
63. *Nelson A, Eastwood D, Wang T, Carlson K, Michaelis L, Pasquini M, Hari P, Chitambar C, **Fenske T**, Graham M, Hamadani M, D'Souza A, Atallah E. A statistical model for predicting neutropenic fever. 2014 American Society of Hematology Meeting (San Francisco, CA).
64. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, *Shah N, **Fenske TS**, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Comparative analysis of "double-hit" lymphoma cases by genetic subtype. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
65. Veltri L, Dhakal B, Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, Esselman J, Pasquini MC, **Fenske TS**, Hari P, Hamadani M, Kanate AS. Chemomobilization with ICE

- (ifosfamide, carboplatin and etoposide) is superior to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
66. Diefenbach CS, Li H, Kahl BS, Robertson MJ, Cohen J, Advani RH, Ambinder R, **Fenske TS**, Ansell SM. A phase 1 study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 67. *Giever TA, Giever ER, Foy PC, Baumann-Kreuziger L, Michaelis L, Carlson K, **Fenske TS**, Hamadani M, Rilling WE, Hari PN, Atallah EL. Incidence of line related venous thromboembolism in peripherally inserted central venous catheters via the brachiocephalic veins vs tunneled chest central venous catheters via the internal jugular vein in patients with hematologic malignancies. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 68. *Nelson A, Eastwood D, Wang T, Carlson K, Michaelis LC, Pasquini MC, Hari P, Chitambar CR, **Fenske TS**, Graham MB, Hamadani M, D'Souza A, Atallah E. A statistical model for predicting neutropenic fever. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 69. Burris HA, Patel MR, **Fenske TS**, O'Connor OA, Deng C, Brander DM, Gutierrez M, Jones S, Kuhn J, Miskin HP, Sportelli P, Vakkalanka S, Flinn I. TGR-1202, a Novel Once Daily PI3K γ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 70. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine LS, Shea TC, Cashen AF, **Fenske TS**, Barr PM, Leblanc M, Fisher RI, Smith SM, Friedberg JW. Results of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma: US Intergroup Study SWOG S1106. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 71. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, **Fenske TS**, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Analysis of "double-hit" lymphoma cases by genetic subtype. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 72. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL): characteristics, outcomes, and prognostication among a large multicenter cohort. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 73. O'Brien S, Burris H, Patel M, Buger M, **Fenske T**, O'Connor O, Brander D, Schreeder M, Miskin H, Sportelli P, Flinn I. TGR-1202, a novel once daily PI3K γ inhibitor, demonstrates clinical activity with a favorable & differentiated safety profile as a single agent and in combination with a novel glycoengineered anti-CD20 mAb, ublituximab, in patients with rel/ref CLL. 2015 International Workshop on Chronic Lymphocytic Leukemia (Sydney, Australia).
 74. **Fenske TS**, *Graff TM, Ahn KW, DiGilio A, Smith SM, Sureda AM, Hamadan M. Reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) provides durable progression-free survival (PFS) in a subset of diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous (auto) HCT. 2015 American Society of Hematology Meeting (Orlando, FL).
 75. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine LS, Shea TC, Cashen AF, Blum K, **Fenske TS**, Barr PM, Leblanc M, Fisher RI, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Pre-transplant R-Bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of SWOG S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma. 2015 American Society of Hematology Meeting (Orlando, FL).
 76. Mussetti A, Kanate AS, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Ciurea S, Armand P, Salit R, **Fenske TS**, Smith SM, Sureda A, Bolanos Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoma malignancies. 2015 American Society of Hematology Meeting (Orlando, FL).
 77. *Kapke JT, *Epperla N, *Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with classical Hodgkin's

- lymphoma (cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
78. *Epperla N, *Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
 79. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, **Fenske TS**, Advani RH, Kahl BS, Ansell SM. Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2015 American Society of Hematology Meeting (Orlando, FL).
 80. *Dhakal B, *Epperla N, Ramalingam S, Shuff J, Rein L, Banerjee A, Siker M, Hoskin P, Hari P, D'Souza A, Atallah E, **Fenske TS**, Erickson B, Hamadani M. Local control of ocular adenexal lymphoproliferative disorders (OALD): similar outcomes in MALT and non-MALT histologies. 2015 American Society of Hematology Meeting (Orlando, FL).
 81. O'Connor OA, Flinn I, Patel MR, **Fenske TS**, Deng C, Brander DM, Gutierrez M, Jones S, Kuhn J, Miskin HP, Sportelli P, Vakkalanka S, Burris HA. TGR-1202, a Novel Once Daily PI3K? Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. 2015 American Society of Hematology Meeting (Orlando, FL).
 82. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske T**, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, Hamadani M, Pasquini M. Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). A Joint Study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). 2015 American Society of Hematology Meeting (Orlando, FL).
 83. *Singavi AK, *Kapte JT, Levin A, Banerjee A, Visotcky A, Zhu F, Hamadani M, Hari PN, **Fenske TS**. Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
 84. Hamdani M, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Rizzo JD, Saber W, Drobyski W, Arce-Lara C, D'Souza A, **Fenske TS**, Cumpston A, Bunner P, Craig M, Hari PN, Kanate AS. Prospective, Multicenter Phase II Clinical Trial of Atorvastatin-based Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT). 2016 Tandem BMT Meetings (Honolulu, HI).
 85. Karmali R, Ghosh N, Rocha V, Ahn K, DiGilio A, Armande P, Salit R, **Fenske T**, Smith S, Sureda A, Wagner-Johnston N, Bolanos Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphoma. 2016 Tandem BMT Meetings (Honolulu, HI).
 86. *Thompson JR, Drobyski WR, D'Souza AD, **Fenske TS**, Hamadan M, Hari PN, Pasquini MC, Saber W, Rizzo JD. Etanercept for late onset idiopathic pneumonia syndrome. 2016 Tandem BMT Meetings (Honolulu, HI).
 87. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske TS**, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumendil A, Hamadani M, Pasquini M. Allogeneic transplantation for relapsed / refractory follicular lymphoma. A joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). 2016 European Blood and Marrow Transplantation Annual Meeting (Velencia, Spain).
 88. Voshtina E, Hamadani M, **Fenske T**, Pasquini T, D'Souza A, Saber W, Rizzo R, Drobyski W, Hari P, Shah N. Outcomes of obese elderly patients undergoing allogeneic transplant for myeloid malignancies. 2016 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
 89. *Epperla N, Hamadani M, Ahn KW, Kanate AS, Calzada O, Farmer L, Tallarico M, Nabhan C, Costa LJ, Kenkre V, Ghosh N, Cohen J, Hari PH, Oak E, Cashen A, **Fenske TS**. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 90. Burris HA, Flinn IW, Lunning M, Vose J, Fowler N, Nastoupil L, O'Brien S, Schreeder MT, Patel MR, **Fenske TS**, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term follow-up of the once-daily PI3K? inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Meta-analysis of

- TGR-1202 as a single agent and in combination with ublituximab. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
91. *Epperla N, Greenwell B, Staton AD, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilov AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 92. Burris HA, Flinn IW, Lunning M, Vose J, Fowler N, Nastoupil L, O'Brien S, Schreeder MT, Patel MR, **Fenske TS**, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term follow-up of the once-daily PI3K? inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Meta-analysis of TGR-1202 as a single agent and in combination with ublituximab. 2016 European Hematology Association Annual Meeting (Copenhagen, Denmark).
 93. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, **Fenske TS**, Advani RH, Kahl BS, Ansell SM. (check title) Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2016 International Symposium on Hodgkin Lymphoma (Cologne, Germany).
 94. Levin A, Kleman A, Rein L, Tarima S, Michaelis L, Carlson KS, Hamadani M, **Fenske TS**, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute promyelocytic leukemia (APL) treated in community vs. academic hospitals. 2016 American Society of Hematology Meeting (San Diego, CA).
 95. Hamlin PA, Miller C, **Fenske TS**, Pandey A, Coffey GP, Birrell M, Leeds JM, Sabalvaro-Torres A, Kim Y, Curnutte JT, Michelson GC. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase IIa study in patients relapsed/refractory B cell malignancies. 2016 American Society of Hematology Meeting (San Diego, CA).
 96. Atallah E, Michaelis LC, Carlson KB, D'Souza A, **Fenske TS**, Pasquini MC, Hamadani M, Baim A, Guhl J, Hari P. Phase I study of combination chemotherapy plus ixazomib in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma (ALL). 2016 American Society of Hematology Meeting (San Diego, CA).
 97. *Epperla N, Maddocks KJ, Chavez JC, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Peker D, Forero-Torres A, Flowers C, **Fenske TS**, Cohen JB, Hamadani M, Costa LJ. Diffuse large B-cell lymphoma with primary treatment failure: Identification of ultra-high risk patients and benchmarking for experimental therapies. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
 98. *Epperla N, Costa LJ, Reddy N, Maddocks KJ, Karmali R, Bachanova V, Umyarova E, Zhou Z, Glenn M, Chavez JC, Hernandez-Ilizaliturri FJ, Costa C, Hossain NM, Calzada O, Al-Mansour Z, Xavier A, Evens A, Chhabra S, Jaglal MV, Barta SK, Lansigan F, Flowers C, **Fenske TS**, Cohen JB, Hamadani M. Primary failure diffuse large B-cell lymphoma: early autologous or donor hematopoietic cell transplantation no effective in patients with ultra-high risk features. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
 99. Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Gupta G, Gascoyne RD, Evens AM, Jaffe E. Gray zone lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): pathologic classification and clinical outcomes from a multicenter consensus analysis. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
 100. Landsburg DJ, Reddy NM, Howlett C, Mato AR, Kaplan JB, Behdad A, Petrich AM, Maly J, Blum KA, Chavez JC, Shaoying L, Medeiros LJ, Falkiewicz MK, Hill BT, *Singavi A, **Fenske TS**, Gerson J, Barta SK, Pallawi T, Hernandez-Iliazlaturri, Costa C, Lansigan F, Calzada O, Cohen J, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Cassaday RD. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
 101. Voshtina E, Dzabo A, Hamadani M, **Fenske TS**, D'Souza A, Saber W, Drobyski W, Hari P, Shah N. Outcomes of obese elderly patients undergoing allogeneic stem cell transplant for myeloid malignancies. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
 102. *Epperla N, Staton AD, Greenwell B, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Risk stratification of mantle

- cell lymphoma patients using MIPI, Ki67 percentage and complex cytogenetics. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
103. Haverkos BM, Schowinsky J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, **Fenske TS**, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens D, Nakamura R, Gutman J, Devine SM. Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
 104. Kanate AS, Olteanu H, Ahn KW, DiGilio A, Sureda A, **Fenske TS**, Smith SM, Hamadani M. Allogeneic hematopoietic cell transplantation (alloHCT) for extranodal natural killer (NK)/T-Cell Lymphoma, Nasal Type (ENKL): A CIBMTR analysis. 2017 Tandem BMT Meetings (Orlando, FL).
 105. *Epperla N, Ahn KW, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine SM, Jaglowski S, Kharfan-Dabaja M, Rezvani A, Smith SM, Sureda S, **Fenske TS**, Hamadani M. Rituximab (R) versus non-rituximab (NR) containing reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in B-cell non-Hodgkin lymphomas (B-NHL): A CIBMTR analysis. 2017 Tandem BMT Meetings (Orlando, FL).
 106. Casulo C, Friedberg JW, Ahn KW, DiGilio A, Sureda A, **Fenske TS**, Smith SM, Hamadani M. Autologous transplantation (autoHCT) is associated with improved overall survival (OS) in follicular lymphoma (FL) patients (pts) experiencing early therapy failure after frontline chemo-immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis. 2017 Tandem BMT Meetings (Orlando, FL).
 107. Drobyski W, Szabo A, Hari P, Hamadani M, Herbert K, Keever-Taylor C, D'Souza A, Eapen M, **Fenske TS**, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw BE, Yim S, Pasquini MC. Results of a phase II clinical trial of tocilizumab, tacrolimus and methotrexate (Toc/Tac/MTX) for the prevention of acute graft versus host disease (GVHD) and matched case control comparison to Tac/MTX after allogeneic stem cell transplantation. 2017 Tandem BMT Meetings (Orlando, FL).
 108. *Epperla N, Shah NN, He F, Kodali D, Kleman A, Ahn KW, Hari PN, Pasquini M, D'Souza AD, Saber W, **Fenske TS**, Craig MD, Kanate AS, Bachanova V, Hamadani M. Post-relapse survival in lymphoma patients after experiencing therapy failure following allogeneic hematopoietic cell transplantation. 2017 Tandem BMT Meetings (Orlando, FL).
 109. Greenwell IB, Valla K, Caulfield S, Switchenko JM, Staton A, Flowers C, Maly J, Blum KA, Park SI, Danilov AV, Epperla N, **Fenske TS**, Hamadani M, Cohen JB. Outcomes in mantle cell lymphoma for elderly patients undergoing autologous stem cell transplant in CR1. 2017 Tandem BMT Meetings (Orlando, FL).
 110. Abidi MA, Stoll C, D'Souza A, Pasquini MC, Saber W, **Fenske TS**, Rizzo JD, Drobyski W, Keever-Taylor CA, Hari, P. Importance of site preparation in reducing the risk of bacterial contamination during bone marrow harvest. 2017 Tandem BMT Meetings (Orlando, FL).
 111. *Epperla N, **Fenske TS**, Costa L. MYC+ Relapsed and Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Impact of additional "hits" and outcomes with subsequent therapy. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 112. Godfrey J, Smith SM, Ahn KW, DiGilio A, **Fenske T**, Sureda A, Hamadani M. Autologous (auto) Versus Matched Sibling Donor (MSD) or Matched Unrelated Donor (MUD) Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) in Follicular Lymphoma (FL) Patients (pts) with Early Chemoimmunotherapy Failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 113. *Epperla N, Strelec LE, Saba R, Kodali D, Esan O, Yang DT, Mato AR, Hamadani M, **Fenske TS**, Kenkre VP, Kanate AS, Svoboda J, Cashen AF, Shah NN. Assessment of optimal management of grade 3A follicular lymphoma (FL3A): a multicenter study. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 114. Andreadis C, **Fenske TS**, Hill BT, Stiff PJ, Grenblatt DL, His ED, Kelley T, Richards KL, Kostakoglu L, Schoder H, Jung SH, Pitcher B, Pike K, Plona T, Baugher R, Mellott S, Bartlett NL, Leonard J, Shea TC, Devine SM. IRONCLAD: A randomized phase III study of ibrutinib Or No Consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory Activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL). 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 115. Hamlin JA, Farber C, **Fenske TS**, Khatcheressian J, Miller C, Munoz J, Patel M, Smith S, Stevens D, Pandey A, Birrell M, Leeds JM, Wang YL, Coffey GP, Curnutte JT. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2

- study in patients with relapsed/ refractory B cell malignancies. 2017 European Haematology Association (Madrid, Spain).
116. Hamlin JA, Farber C, **Fenske TS**, Khatcheressian J, Miller C, Munoz J, Patel M, Schreeder M, Smith S, Stevens D, Pandey A, Birrell M, Leeds JM, Wang YL, Coffey GP, Curnutte JT. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/ refractory B cell malignancies. 2017 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 117. **Fenske TS**, Majewski DM, Baxter-Lowe LA. Use of oligotyping to detect novel HLA-DQ alleles and to assess linkage disequilibrium between HLA-DQA1 and HLA-DQB1 alleles. *Human Immunology* 34 (suppl 1): 20, 1992. 1992 American Association of Immunology Meeting (Minneapolis, MN).
 118. **Fenske TS**, Farner NL, de Jong JLO, O'Shea JJ, Sondel PM. Interleukin-2 mediated activation of JAK3 in the absence of a detectable 64 kDa common gamma chain. *FASEB Journal* 10 (6): A1303, 1996. 1996 FASEB/ASBMB Annual Meeting. (New Orleans, LA).
 119. **Fenske TS**. Bilateral leg pain and weakness in a patient with polycythemia vera. American College of Physicians/ American Society of Internal Medicine, Wisconsin Chapter, Annual Meeting, Sept 2001. (Milwaukee, WI).
 120. **Fenske TS**, Kahl BS, Smith EP, Atkinson E, Garry-McCoy A, Mitchell TL, Eckstein L, Flynn B, McMannes J, Eickhoff J, Longo WL. High dose therapy with thioetpa, etoposide, total body irradiation and involved field radiation followed by autologous stem cell rescue for indolent histology and mantle cell non-Hodgkin lymphoma. 2002 ASH Meeting, Abstract 5461 (Philadelphia, PA).
 121. **Fenske TS**, Mathews V, Pengue G, Hanson P, Bogue M, McLeod HL, Graubert TA. Genetic basis of susceptibility to alkylator chemotherapy-related leukemia. 2003 ASH Meeting, Abstract 1348 Oral Presentation (San Diego, CA).
 122. Pengue G, Mathews V, **Fenske T**, Hanson P, Marrus S, Riaz N, Graubert TA. Targeting AML1-ETO to the hematopoietic stem cell compartment induces myeloproliferative disease in mice. 2003 American Society of Hematology Meeting, Abstract 756, Oral Presentation (San Diego, CA).
 123. Devine SM, Hallemeier C, **Fenske T**, Vij R, DiPersio JF, Adkins DA. Reduced intensity allografts for acute myeloid leukemia: defining the role of conditioning and donor alloreactivity. 2004 American Society of Hematology Meeting (San Diego, CA).
 124. Edwin D, McMahon C, Kreisel F, Bogue M, **Fenske TS**, Graubert TA. A mouse model of alkylator-induced myelodysplastic syndrome. 2005 American Society of Hematology Meeting, Oral Presentation (Atlanta, GA).
 125. Edwin D, **Fenske TS**, McMahon C, Mathews V, Bogue M, Province M, Cheverud J, McLeod H, Graubert TA. Susceptibility to alkylator-induced cancer is a heritable trait. 2005 American Society of Hematology Meeting, Poster (Atlanta, GA).
 126. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the treatment of high titer acquired factor VIII inhibitors refractory to conventional chemotherapy. 2005 American Society of Hematology Meeting, Poster (Atlanta, GA).
 127. *Benjamin H, **Fenske TS**, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. 2007 American Society of Hematology Meeting (Atlanta, GA).
 128. **Fenske TS**, Hari P, Carreras J, Zhang M, Kamble R, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Pre-transplant rituximab therapy is associated with improved progression-free and overall survival in patients undergoing autologous stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). 2007 American Society of Hematology Meeting, Oral Presentation (Atlanta, GA).
 129. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, DiPersio JF, Bartlett NL. A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. 2009 American Society of Hematology Meeting (New Orleans, LA).
 130. *Randhawa J, Bredeson C, **Fenske T**, Hari P, Palmer J, Saad A, Olteanu H, Atallah E. Outpatient Hypomethylating therapy for acute myelogenous leukemia (AML) can induce sustained responses with low induction mortality. 2009 American Society of Hematology Meeting (New Orleans, LA).
 131. Connelly J, Harrington A, Kroft S, Ho K, **Fenske T**, Malkin M. Methotrexate-induced CNS Hodgkin-like lymphoproliferative disorder: a case report. 2009 Joint Meeting of the Society for NeuroOncology and the American Association of Neurological Surgeons / Congress of Neurological Surgeons (New Orleans, LA).
 132. Hari P, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, **Fenske TS**. Allogeneic transplantation (AlloHCT) for patients with mantle cell lymphoma (MCL) progressing after autologous transplantation

- (AutoHCT). 2011 International Conference on Malignant Lymphoma, Oral Presentation (Lugano, Switzerland).
133. **Fenske TS**, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, Hari P. Outcomes of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. 2011 International Conference on Malignant Lymphoma, Oral Presentation (Lugano, Switzerland).
 134. Vose JM, Carter SL, Burns L, Ayala E, Press O, Moskowitz C, Stadtmauer E, Mineshi S, Ambinder R, **Fenske T**, Difronzo N, Horowitz M, Tomblyn M. Randomized phase III trial of 131 Iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). 2011 American Society of Hematology Meeting, Oral Presentation (San Diego, CA).
 135. *Cornell RF, Thompson J, Drobyski WR, **Fenske TS**, Horowitz MM, Palmer JM, Pasquini MC, Saad AA, Rizzo JD, Saber W, Zhang MJ, Zhong X, Hari P. Risk factors and clinical features of autologous graft-versus-host disease/ engraftment syndrome after autologous hematopoietic cell (HCT) transplantation. 2012 Tandem BMT Meetings (San Diego CA).
 136. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, **Fenske TS**, Cashen AF, Wagner-Johnston N, Carson K, Bartlett NL. A phase II multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. 2012 American Society of Hematology Meeting (Atlanta, GA).
 137. Chang JE, Zhang C, Kim K, Kirby R, Volk L, Werndli J, Go R, Weiss M, Blank J, Farnen J, Cole C, Bseiso A, Volk M, Bayer G, Traynor A, Mansky P, **Fenske TS**, Kahl BS. Bendamustine + rituximab (BR) chemoimmunotherapy and maintenance lenalidomide in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): A Wisconsin Oncology Network (WON) Study. 2012 American Society of Hematology Meeting (Atlanta, GA).
 138. Wirk B, Burns L, **Fenske TS**, Hu Z, Laport G, Montoto S, Maloney D, Saber W. Clinical outcomes of hematopoietic cell transplantation in patients with diffuse large B cell lymphoma transformed from follicular lymphoma. 2013 Tandem BMT Meetings, Oral Presentation (Salt Lake City, UT).
 139. *Xia C, Zhong X, Dhokal B, Thompson J, **Fenske T**, Esselmann J, Keever-Taylor C, Padmanabhan A, Hari P. Plerixafor overcomes the adverse effect of diabetes on hematopoietic progenitor cell mobilization. 2013 Tandem BMT Meetings (Salt Lake City, UT).
 140. Hintzke M, **Fenske T**, Kroft SH, Olteanu O, Harrington AM. CD30 expression in non-Hodgkin B-cell lymphoma. 2013 United States & Canadian Academy of Pathology Annual Meeting (Baltimore, MD).
 141. *Cornell RF, *Randhawa JK, Drobyski W, Zhong X, *Thompson J, Horowitz MM, **Fenske T**, Palmer J, Pasquini MC, Saber W, Thomas M, Zhang M, Hari PN. Risk factors and clinical features of engraftment syndrome after autologous hematopoietic cell transplantation (AHCT). 2013 Tandem BMT Meetings, Oral Presentation, (Salt Lake City, UT).
 142. *Giever TA, Richter EL, Broge KM, Foy PC, Blust LS, Palmer JM, **Fenske TS**, Rilling WS, Hari P, Atallah EL. High incidence of venous thromboembolism in patients with hematological malignancies related to upper extremity peripherally inserted central venous catheters. 2013 American Society of Clinical Oncology Meeting, Poster (Chicago, IL).
 143. *Pingali R, Jewell S, Bast M, Thompson J, Eastwood D, Bartlett NL, Armitage JO, Wagner-Johnston N, Vose JM, **Fenske TS**. Clinical or survival benefit to routine surveillance imaging in classical Hodgkin lymphoma patients in first complete remission. 2013 American Society of Clinical Oncology Meeting, Oral Presentation (Chicago, IL).
 144. Evens AM, Hamlin PA, Advani RH, Fanale M, Smith SM, Bociek G, **Fenske TS**, Petrich A, Winter J, Gordon L. Sequential brentuximab vedotin (BV) with adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma: preliminary toxicity findings from a phase II window study. 2013 International Symposium on Hodgkin Lymphoma (Cologne, Germany).
 145. Gandhi MD, Petrich AM, Cassady R, Press O, Shah KA, Whyman JD, Lansigan F, Zelenetz A, *Shah N, **Fenske T**, Hernandez-Ilizaliturri FJ, Lee JX, Barta SK, Karmali R, Camille A, Smith S, Vose J, Dalal N, Nabhan C, Peace D, Jovanovic B, Sohani A, Evens A, Castillo J, Abramson JS. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): A large multicenter retrospective analysis. 2013 American Society of Hematology Meeting, Oral Presentation (New Orleans, GA).
 146. **Fenske TS**, Kim K, Zhang C, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor A, Mattison RJ, Kahl BS. Weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network Phase II study. 2013 American Society

- of Hematology Meeting, Poster (New Orleans, GA).
147. Gandhi M, Evens A, **Fenske TS**, Hamlin P, Coiffier B, Ghosh N, Moskowitz A, Petrich A, Engert A, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio S, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event. 2013 American Society of Hematology Meeting (New Orleans, GA).
 148. *Pingali R, Vose JM, Wagner-Johnson N, Loberiza FR, **Fenske TS**, Jewell S, Bast M, Bartlett NL, Armitage JO. Lack of clinical benefit for routine surveillance imaging for diffuse large B-cell lymphoma in first complete remission. 2013 American Society of Hematology Meeting, Poster (New Orleans, GA).
 149. *Graff T, *Singavi A, Schmidt W, Eastwood D, Drobyski W, Horowitz M, Palmer J, Pasquini M, Rizzo D, Saber W, Hari P, **Fenske TS**. Safety of outpatient autologous hematopoietic cell transplantation (AuHCT) for multiple myeloma and lymphoma. 2014 Tandem BMT Meetings (Dallas, TX).
 150. *Peswani N, Carlson KS, Chitambar CR, **Fenske TS**, Hari P, Michaelis L, Blust LS, Atallah H. Short time to ATRA administration and reduction of early mortality in patients with APL. 2014 American Society of Clinical Oncology Meeting (Chicago, IL).
 151. *Chandran R, Gardiner SK, **Fenske TS**, Spurgeon SE. Survival trends in T cell prolymphocytic leukemia: a SEER database analysis. 2014 Ultmann Chicago Lymphoma Symposium (Chicago, IL).
 152. *Peswani N, **Fenske T**, Hari P, Carlson KS, Michaelis L, Chitambar C, Baumann-Kreuziger L, Atallah E. D-dimer kinetics, chemotherapy and the risk of bleeding in patients with acute promyelocytic leukemia. 2014 World Congress on Controversies in Thrombosis and Hemostasis (Berlin, Germany).
 153. Burris HA, Patel MR, Brander D, O'Connor OA, Deng C, **Fenske TS**, Gutierrez M, Jones SF, Kuhn JG, Miskin HP, Sportelli P, Vakkalank S, Flinn I. TGR-1202 a novel once daily PI3K? inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. 2014 American Society of Hematology Meeting (San Francisco, CA).
 154. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, **Fenske T**, Longo W, Devine SM, Nadamanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced intensity conditioning (RIC) with rituximab yields excellent outcomes after allogeneic hematopoietic cell transplantation (alloHCT) for relapsed follicular lymphoma (FL): A phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN). 2014 American Society of Hematology Meeting (San Francisco, CA).
 155. Kritharis A, Kanakry JA, Sehn LH, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Lossos IS, Press OW, **Fenske T**, Friedberg JW, Vose JM, Blum KA, Evens AM. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL): analysis of tumor immunophenotype and critical examination of therapy with associated impact on outcome. 2014 American Society of Hematology Meeting (San Francisco, CA).
 156. *Peswani N, Baumann-Kreuziger L, Carlson K, Michaelis L, Hari P, **Fenske T**, Chitambar C, Atallah E. D-dimer kinetics, chemotherapy, and the risk of bleeding in acute promyelocytic leukemia. 2014 American Society of Hematology Meeting (San Francisco, CA).
 157. *Nelson A, Eastwood D, Wang T, Carlson K, Michaelis L, Pasquini M, Hari P, Chitambar C, **Fenske T**, Graham M, Hamadani M, D'Souza A, Atallah E. A statistical model for predicting neutropenic fever. 2014 American Society of Hematology Meeting (San Francisco, CA).
 158. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, *Shah N, **Fenske TS**, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Comparative analysis of "double-hit" lymphoma cases by genetic subtype. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 159. Veltri L, Dhakal B, Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, Esselman J, Pasquini MC, **Fenske TS**, Hari P, Hamadani M, Kanate AS. Chemomobilization with ICE (ifosfamide, carboplatin and etoposide) is superior to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 160. Diefenbach CS, Li H, Kahl BS, Robertson MJ, Cohen J, Advani RH, Ambinder R, **Fenske TS**, Ansell SM. A phase 1 study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 161. *Giever TA, Giever ER, Foy PC, Baumann-Kreuziger L, Michaelis L, Carlson K, **Fenske TS**, Hamadani M, Rilling WE, Hari PN, Atallah EL. Incidence of line related venous thromboembolism in

- peripherally inserted central venous catheters via the brachiocephalic veins vs tunneled chest central venous catheters via the internal jugular vein in patients with hematologic malignancies. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
162. *Nelson A, Eastwood D, Wang T, Carlson K, Michaelis LC, Pasquini MC, Hari P, Chitambar CR, **Fenske TS**, Graham MB, Hamadani M, D'Souza A, Atallah E. A statistical model for predicting neutropenic fever. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 163. Burris HA, Patel MR, **Fenske TS**, O'Connor OA, Deng C, Brander DM, Gutierrez M, Jones S, Kuhn J, Miskin HP, Sportelli P, Vakkalanka S, Flinn I. TGR-1202, a Novel Once Daily PI3K? Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
 164. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine LS, Shea TC, Cashen AF, **Fenske TS**, Barr PM, Leblanc M, Fisher RI, Smith SM, Friedberg JW. Results of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma: US Intergroup Study SWOG S1106. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 165. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, **Fenske TS**, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Analysis of "double-hit" lymphoma cases by genetic subtype. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 166. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL): characteristics, outcomes, and prognostication among a large multicenter cohort. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
 167. O'Brien S, Burris H, Patel M, Buger M, **Fenske T**, O'Connor O, Brander D, Schreeder M, Miskin H, Sportelli P, Flinn I. TGR-1202, a novel once daily PI3Kd inhibitor, demonstrates clinical activity with a favorable & differentiated safety profile as a single agent and in combination with a novel glycoengineered anti-CD20 mAb, ublituximab, in patients with rel/ref CLL. 2015 International Workshop on Chronic Lymphocytic Leukemia (Sydney, Australia).
 168. **Fenske TS**, *Graff TM, Ahn KW, DiGilio A, Smith SM, Sureda AM, Hamadan M. Reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) provides durable progression-free survival (PFS) in a subset of diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous (auto) HCT. 2015 American Society of Hematology Meeting (Orlando, FL).
 169. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine LS, Shea TC, Cashen AF, Blum K, **Fenske TS**, Barr PM, Leblanc M, Fisher RI, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Pre-transplant R-Bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of SWOG S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma. 2015 American Society of Hematology Meeting (Orlando, FL).
 170. Mussetti A, Kanate AS, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Ciurea S, Armand P, Salit R, **Fenske TS**, Smith SM, Sureda A, Bolanos Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoma malignancies. 2015 American Society of Hematology Meeting (Orlando, FL).
 171. *Kapke JT, *Epperla N, *Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with classical Hodgkin's lymphoma (cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
 172. *Epperla N, *Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
 173. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, **Fenske TS**, Advani RH, Kahl BS, Ansell SM. Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in

- Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2015 American Society of Hematology Meeting (Orlando, FL).
174. *Dhakal B, *Epperla N, Ramalingam S, Shuff J, Rein L, Banerjee A, Siker M, Hoskin P, Hari P, D'Souza A, Atallah E, **Fenske TS**, Erickson B, Hamadani M. Local control of ocular adenexal lymphoproliferative disorders (OALD): similar outcomes in MALT and non-MALT histologies. 2015 American Society of Hematology Meeting (Orlando, FL).
175. O'Connor OA, Flinn I, Patel MR, **Fenske TS**, Deng C, Brander DM, Gutierrez M, Jones S, Kuhn J, Miskin HP, Sportelli P, Vakkalanka S, Burris HA. TGR-1202, a Novel Once Daily PI3K? Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. 2015 American Society of Hematology Meeting (Orlando, FL).
176. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske T**, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, Hamadani M, Pasquini M. Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). A Joint Study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). 2015 American Society of Hematology Meeting (Orlando, FL).
177. *Singavi AK, *Kapke JT, Levin A, Banerjee A, Visotcky A, Zhu F, Hamadani M, Hari PN, **Fenske TS**. Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
178. Hamdani M, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Rizzo JD, Saber W, Drobyski W, Arce-Lara C, D'Souza A, **Fenske TS**, Cumpston A, Bunner P, Craig M, Hari PN, Kanate AS. Prospective, Multicenter Phase II Clinical Trial of Atorvastatin-based Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT). 2016 Tandem BMT Meetings (Honolulu, HI).
179. Karmali R, Ghosh N, Rocha V, Ahn K, DiGilio A, Armande P, Salit R, **Fenske T**, Smith S, Sureda A, Wagner-Johnston N, Bolanos Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphoma. 2016 Tandem BMT Meetings (Honolulu, HI).
180. *Thompson JR, Drobyski WR, D'Souza AD, **Fenske TS**, Hamadan M, Hari PN, Pasquini MC, Saber W, Rizzo JD. Etanercept for late onset idiopathic pneumonia syndrome. 2016 Tandem BMT Meetings (Honolulu, HI).
181. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske TS**, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumendil A, Hamadani M, Pasquini M. Allogeneic transplantation for relapsed / refractory follicular lymphoma. A joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). 2016 European Blood and Marrow Transplantation Annual Meeting (Valencia, Spain).
182. Voshtina E, Hamadani M, **Fenske T**, Pasquini T, D'Souza A, Saber W, Rizzo R, Drobyski W, Hari P, Shah N. Outcomes of obese elderly patients undergoing allogeneic transplant for myeloid malignancies. 2016 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
183. *Epperla N, Hamadani M, Ahn KW, Kanate AS, Calzada O, Farmer L, Tallarico M, Nabhan C, Costa LJ, Kenkre V, Ghosh N, Cohen J, Hari PH, Oak E, Cashen A, **Fenske TS**. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
184. Burris HA, Flinn IW, Lunning M, Vose J, Fowler N, Nastoupil L, O'Brien S, Schreeder MT, Patel MR, **Fenske TS**, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term follow-up of the once-daily PI3K? inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Meta-analysis of TGR-1202 as a single agent and in combination with ublituximab. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
185. *Epperla N, Greenwell B, Staton AD, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilove AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
186. Burris HA, Flinn IW, Lunning M, Vose J, Fowler N, Nastoupil L, O'Brien S, Schreeder MT, Patel MR, **Fenske TS**, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin

- HP, Weiss MS, O'Connor OA. Long-term follow-up of the once-daily PI3K^γ inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Meta-analysis of TGR-1202 as a single agent and in combination with ublituximab. 2016 European Hematology Association Annual Meeting (Copenhagen, Denmark).
187. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, **Fenske TS**, Advani RH, Kahl BS, Ansell SM. (check title) Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2016 International Symposium on Hodgkin Lymphoma (Cologne, Germany).
188. Levin A, Kleman A, Rein L, Tarima S, Michaelis L, Carlson KS, Hamadani M, **Fenske TS**, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute promyelocytic leukemia (APL) treated in community vs. academic hospitals. 2016 American Society of Hematology Meeting (San Diego, CA).
189. Hamlin PA, Miller C, **Fenske TS**, Pandey A, Coffey GP, Birrell M, Leeds JM, Sabalvaro-Torres A, Kim Y, Curnutte JT, Michelson GC. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase IIa study in patients relapsed/refractory B cell malignancies. 2016 American Society of Hematology Meeting (San Diego, CA).
190. Atallah E, Michaelis LC, Carlson KB, D'Souza A, **Fenske TS**, Pasquini MC, Hamadani M, Baim A, Guhl J, Hari P. Phase I study of combination chemotherapy plus ixazomib in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma (ALL). 2016 American Society of Hematology Meeting (San Diego, CA).
191. *Epperla N, Maddocks KJ, Chavez JC, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Peker D, Forero-Torres A, Flowers C, **Fenske TS**, Cohen JB, Hamadani M, Costa LJ. Diffuse large B-cell lymphoma with primary treatment failure: Identification of ultra-high risk patients and benchmarking for experimental therapies. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
192. *Epperla N, Costa LJ, Reddy N, Maddocks KJ, Karmali R, Bachanova V, Umyarova E, Zhou Z, Glenn M, Chavez JC, Hernandez-Ilizaliturri FJ, Costa C, Hossain NM, Calzada O, Al-Mansour Z, Xavier A, Evens A, Chhabra S, Jaglal MV, Barta SK, Lansigan F, Flowers C, **Fenske TS**, Cohen JB, Hamadani M. Primary failure diffuse large B-cell lymphoma: early autologous or donor hematopoietic cell transplantation no effective in patients with ultra-high risk features. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
193. Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Gupta G, Gascoyne RD, Evens AM, Jaffe E. Gray zone lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): pathologic classification and clinical outcomes from a multicenter consensus analysis. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
194. Landsburg DJ, Reddy NM, Howlett C, Mato AR, Kaplan JB, Behdad A, Petrich AM, Maly J, Blum KA, Chavez JC, Shaoying L, Medeiros LJ, Falkiewicz MK, Hill BT, *Singavi A, **Fenske TS**, Gerson J, Barta SK, Pallawi T, Hernandez-Iliazlaturri, Costa C, Lansigan F, Calzada O, Cohen J, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Cassaday RD. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
195. Voshtina E, Dzabo A, Hamadani M, **Fenske TS**, D'Souza A, Saber W, Drobyski W, Hari P, Shah N. Outcomes of obese elderly patients undergoing allogeneic stem cell transplant for myeloid malignancies. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
196. *Epperla N, Staton AD, Greenwell B, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Risk stratification of mantle cell lymphoma patients using MIPI, Ki67 percentage and complex cytogenetics. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
197. Haverkos BM, Schowinsky J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, **Fenske TS**, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens D, Nakamura R, Gutman J, Devine SM. Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
198. Kanate AS, Olteanu H, Ahn KW, DiGilio A, Sureda A, **Fenske TS**, Smith SM, Hamadani M. Allogeneic

- hematopoietic cell transplantation (alloHCT) for extranodal natural killer (NK)/T-Cell Lymphoma, Nasal Type (ENKL): A CIBMTR analysis. 2017 Tandem BMT Meetings (Orlando, FL).
199. *Epperla N, Ahn KW, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine SM, Jaglowski S, Kharfan-Dabaja M, Rezvani A, Smith SM, Sureda S, **Fenske TS**, Hamadani M. Rituximab (R) versus non-rituximab (NR) containing reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in B-cell non-Hodgkin lymphomas (B-NHL): A CIBMTR analysis. 2017 Tandem BMT Meetings (Orlando, FL).
 200. Casulo C, Friedberg JW, Ahn KW, DiGilio A, Sureda A, **Fenske TS**, Smith SM, Hamadani M. Autologous transplantation (autoHCT) is associated with improved overall survival (OS) in follicular lymphoma (FL) patients (pts) experiencing early therapy failure after frontline chemo-immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis. 2017 Tandem BMT Meetings (Orlando, FL).
 201. Drobycki W, Szabo A, Hari P, Hamadani M, Herbert K, Keever-Taylor C, D'Souza A, Eapen M, **Fenske TS**, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw BE, Yim S, Pasquini MC. Results of a phase II clinical trial of tocilizumab, tacrolimus and methotrexate (Toc/Tac/MTX) for the prevention of acute graft versus host disease (GVHD) and matched case control comparison to Tac/MTX after allogeneic stem cell transplantation. 2017 Tandem BMT Meetings (Orlando, FL).
 202. *Epperla N, Shah NN, He F, Kodali D, Kleman A, Ahn KW, Hari PN, Pasquini M, D'Souza AD, Saber W, **Fenske TS**, Craig MD, Kanate AS, Bachanova V, Hamadani M. Post-relapse survival in lymphoma patients after experiencing therapy failure following allogeneic hematopoietic cell transplantation. 2017 Tandem BMT Meetings (Orlando, FL).
 203. Greenwell IB, Valla K, Caulfield S, Switchenko JM, Staton A, Flowers C, Maly J, Blum KA, Park SI, Danilov AV, Epperla N, **Fenske TS**, Hamadani M, Cohen JB. Outcomes in mantle cell lymphoma for elderly patients undergoing autologous stem cell transplant in CR1. 2017 Tandem BMT Meetings (Orlando, FL).
 204. Abidi MA, Stoll C, D'Souza A, Pasquini MC, Saber W, **Fenske TS**, Rizzo JD, Drobycki W, Keever-Taylor CA, Hari, P. Importance of site preparation in reducing the risk of bacterial contamination during bone marrow harvest. 2017 Tandem BMT Meetings (Orlando, FL).
 205. *Epperla N, **Fenske TS**, Costa L. MYC+ Relapsed and Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Impact of additional "hits" and outcomes with subsequent therapy. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 206. Godfrey J, Smith SM, Ahn KW, Digilio A, **Fenske T**, Sureda A, Hamadani M. Autologous (auto) Versus Matched Sibling Donor (MSD) or Matched Unrelated Donor (MUD) Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) in Follicular Lymphoma (FL) Patients (pts) with Early Chemoimmunotherapy Failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 207. *Epperla N, Strelec LE, Saba R, Kodali D, Esan O, Yang DT, Mato AR, Hamadani M, **Fenske TS**, Kenkre VP, Kanate AS, Svoboda J, Cashen AF, Shah NN. Assessment of optimal management of grade 3A follicular lymphoma (FL3A): a multicenter study. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 208. Andreadis C, **Fenske TS**, Hill BT, Stiff PJ, Grenblatt DL, His ED, Kelley T, Richards KL, Kostakoglu L, Schoder H, Jung SH, Pitcher B, Pike K, Plona T, Baugher R, Mellott S, Bartlett NL, Leonard J, Shea TC, Devine SM. IRONCLAD: A randomized phase III study of ibrutinib Or No Consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory Activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL). 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
 209. Hamlin JA, Farber C, **Fenske TS**, Khatcheressian J, Miller C, Munoz J, Patel M, Smith S, Stevens D, Pandey A, Birrell M, Leeds JM, Wang YL, Coffey GP, Curnutte JT. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/ refractory B cell malignancies. 2017 European Haematology Association (Madrid, Spain).
 210. Hamlin JA, Farber C, **Fenske TS**, Khatcheressian J, Miller C, Munoz J, Patel M, Schreeder M, Smith S, Stevens D, Pandey A, Birrell M, Leeds JM, Wang YL, Coffey GP, Curnutte JT. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/ refractory B cell malignancies. 2017 International Conference on Malignant Lymphoma (Lugano, Switzerland).

Peer Reviewed Educational Products

1. **Fenske TS**, Pengue G, Graubert TA. Dominant negative effects of the AML1/ETO fusion oncoprotein. *Cell Cycle* 4(1): 33-36, 2005.
2. Hake CR, Graubert TA, **Fenske TS**. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? *Bone Marrow Transplantation* 39(2): 59-70, 2007.